

# Chapter 600 Parts, Form, and Content of Application

<b>601</b>	<b>Content of Provisional and Nonprovisional Applications</b>	<b>60201(c)(2)</b>	Correcting or Updating Inventor Name 37 CFR 1.48(f) – Request Filed On or After September 16, 2012
<b>601.01</b>	Complete Application	<b>60201(c)(3)</b>	[Reserved]
<b>601.01(a)</b>	Nonprovisional Applications Filed Under 35 U.S.C. 111(a)	<b>602.02</b>	New Oath or Substitute for Original Office Finds the Inventor’s Oath or Declaration Defective
<b>601.01(b)</b>	Provisional Applications Filed Under 35 U.S.C. 111(b)	<b>602.03</b>	Foreign Executed Oath
<b>601.01(c)</b>	Conversion to or from a Provisional Application	<b>602.04</b>	Oath or Declaration in Continuing Applications
<b>601.01(d)</b>	Application Filed Without All Pages of Specification	<b>602.05(a)</b>	Oath or Declaration in Continuing Applications Filed On or After September 16, 2012
<b>601.01(e)</b>	Nonprovisional Application Filed Without at Least One Claim	<b>602.05(b)</b>	Oath or Declaration in Continuing Applications Filed Before September 16, 2012
<b>601.01(f)</b>	Applications Filed Without Drawings	<b>602.06</b>	Non-English Oath or Declaration
<b>601.01(g)</b>	Applications Filed Without All Figures of Drawings	<b>602.07</b>	Oath or Declaration Filed in United States as a Designated Office
<b>601.02</b>	Power of Attorney	<b>602.08</b>	Inventor and Application Information
<b>601.03</b>	Correspondence Address	<b>602.08(a)</b>	Inventor Bibliographic Information
<b>601.03(a)</b>	Change of Correspondence Address in Applications Filed On or After September 16, 2012	<b>602.08(b)</b>	Inventor Signature and Name
<b>601.03(b)</b>	Change of Correspondence Address in Applications Filed Before September 16, 2012	<b>602.08(c)</b>	Identification of Application
<b>601.04</b>	National Stage Requirements of the United States as a Designated Office	<b>602.09</b>	Joint Inventors
<b>601.05</b>	Bibliographic Information - Application Data Sheet (ADS)	<b>603</b>	<b>Supplemental Oath or Declaration</b>
<b>601.05(a)</b>	Application Data Sheet (ADS) -- Application Filed On or After September 16, 2012	<b>603.01</b>	Supplemental Oath or Declaration Filed After Allowance
<b>601.05(b)</b>	Application Data Sheet (ADS) in Application Filed Before September 16, 2012	<b>604</b>	<b>Substitute Statements</b>
<b>602</b>	<b>Oaths and Declarations</b>	<b>605</b>	<b>Applicant</b>
<b>602.01</b>	Naming the Inventor; Inventor's Oath or Declaration	<b>605.01</b>	Applicant for Application filed on or after September 16, 2012
<b>602.01(a)</b>	Inventor’s Oath or Declaration in Application Filed On or After September 16, 2012	<b>605.02</b>	Applicant for Application Filed Before September 16, 2012
<b>602.01(b)</b>	Inventor’s Oath or Declaration in Application Filed Before September 16, 2012	<b>606</b>	<b>Title of Invention</b>
<b>602.01(c)</b>	Correction of Inventorship, Name of Inventor, and Order of Names in an Application	<b>606.01</b>	Examiner May Require Change in Title
<b>60201(c)(1)</b>	Correction of Inventorship in an Application – Request Filed On or After September 16, 2012	<b>607</b>	<b>Filing Fee</b>
		<b>607.01</b>	[Reserved]
		<b>607.02</b>	Returnability of Fees
		<b>608</b>	<b>Disclosure</b>
		<b>608.01</b>	Specification
		<b>608.01(a)</b>	Arrangement of Application
		<b>608.01(b)</b>	Abstract of the Disclosure
		<b>608.01(c)</b>	Background of the Invention
		<b>608.01(d)</b>	Brief Summary of Invention
		<b>608.01(e)</b>	[Reserved]
		<b>608.01(f)</b>	Brief Description of Drawings
		<b>608.01(g)</b>	Detailed Description of Invention
		<b>608.01(h)</b>	Mode of Operation of Invention

<b>608.01(i)</b>	Claims	<b>608.02(y)</b>	Return of Drawing
<b>608.01(j)</b>	Numbering of Claims	<b>608.02(z)</b>	Allowable Applications Needing Drawing Corrections or Corrected Drawings
<b>608.01(k)</b>	Statutory Requirement of Claims		
<b>608.01(l)</b>	Claims Present on the Application Filing Date	<b>608.03</b>	Models, Exhibits, Specimens
<b>608.01(m)</b>	Form of Claims	<b>608.03(a)</b>	Handling of Models, Exhibits, and Specimens
<b>608.01(n)</b>	Dependent Claims	<b>608.04</b>	New Matter
<b>608.01(o)</b>	Basis for Claim Terminology in Description	<b>608.04(a)</b>	Matter Not Present in Specification, Claims, or Drawings on the Application Filing Date
<b>608.01(p)</b>	Completeness of Specification	<b>608.04(b)</b>	New Matter by Preliminary Amendment
<b>608.01(q)</b>	Substitute or Rewritten Specification	<b>608.04(c)</b>	Review of Examiner’s Holding of New Matter
<b>608.01(r)</b>	Derogatory Remarks About Prior Art in Specification	<b>608.05</b>	“Sequence Listing,” “Large Tables,” or “Computer Program Listing Appendix” Submitted in ASCII Plain Text or a “Sequence Listing XML” Submitted as XML File Text
<b>608.01(s)</b>	Restoration of Canceled Matter	<b>608.05(a)</b>	Submission of a “Computer Program Listing Appendix”
<b>608.01(t)</b>	Use in Subsequent Application	<b>608.05(b)</b>	ASCII Plain Text Submissions of “Large Tables” and Treatment of Lengthy Tables in a Specification for Patents and Patent Application Publications
<b>608.01(u)</b>	[Reserved]	<b>608.05(c)</b>	Submissions of Biological Sequence Listings
<b>608.01(v)</b>	Marks Used in Commerce and Trade Names	<b>609</b>	<b>Information Disclosure Statement</b>
<b>608.01(w)</b>	Copyright and Mask Work Notices	<b>609.01</b>	Examiner Checklist for Information Disclosure Statements
<b>608.02</b>	Drawing	<b>609.02</b>	Information Disclosure Statements in Continued Examinations or Continuing Applications
<b>608.02(a)</b>	New Drawing — When Replacement is Required Before Examination	<b>609.03</b>	Information Disclosure Statements in National Stage Applications
<b>608.02(b)</b>	Acceptability of Drawings	<b>609.04</b>	Content and Timing Requirements for an Information Disclosure Statement
<b>608.02(c)</b>	Location of Drawings	<b>609.04(a)</b>	Content Requirements for an Information Disclosure Statement
<b>608.02(d)</b>	Complete Illustration in Drawings	<b>609.04(b)</b>	Timing Requirements for an Information Disclosure Statement
<b>608.02(e)</b>	Examiner Determines Completeness and Consistency of Drawings	<b>609.05</b>	Examiner Handling of Information Disclosure Statements
<b>608.02(f)</b>	Modifications in Drawings	<b>609.05(a)</b>	Noncomplying Information Disclosure Statements
<b>608.02(g)</b>	Illustration of Prior Art	<b>609.05(b)</b>	Complying Information Disclosure Statements
<b>608.02(h)</b>	Replacement Drawings		
<b>608.02(i)</b>	Transfer of Drawings From Prior Applications		
<b>608.02(j)</b>	[Reserved]		
<b>-608.02(o)</b>			
<b>608.02(p)</b>	Correction of Drawings		
<b>608.02(q)</b>	[Reserved]		
<b>-608.02(s)</b>			
<b>608.02(t)</b>	Cancellation of Figures		
<b>608.02(u)</b>	[Reserved]		
<b>608.02(v)</b>	Drawing Changes Which Require Annotated Sheets		
<b>608.02(w)</b>	Drawing Changes Which May Be Made Without Applicant’s Annotated Sheets		
<b>608.02(x)</b>	Drawing Corrections or Changes Accepted Unless Notified Otherwise		

- 609.05(c)** Documents Submitted as Part of Applicant's Reply to Office Action
- 609.06** Information Printed on Patent
- 609.07** IDSs Electronically Submitted (e-IDS) Using EFS-Web
- 609.08** Electronic Processing of Information Disclosure Statement

## 601 Content of Provisional and Nonprovisional Applications [R-07.2022]

### 35 U.S.C. 111 Application.

*[Editor Note: Applicable to any patent application filed under this provision on or after December 18, 2013. See [pre-PLT \(AIA\) 35 U.S.C. 111](#) or [pre-AIA 35 U.S.C. 111](#) for the law otherwise applicable.]*

#### (a) IN GENERAL.—

(1) WRITTEN APPLICATION.—An application for patent shall be made, or authorized to be made, by the inventor, except as otherwise provided in this title, in writing to the Director.

(2) CONTENTS.—Such application shall include—

- (A) a specification as prescribed by [section 112](#);
- (B) a drawing as prescribed by [section 113](#); and
- (C) an oath or declaration as prescribed by [section 115](#).

(3) FEE, OATH OR DECLARATION, AND CLAIMS.—The application shall be accompanied by the fee required by law. The fee, oath or declaration, and 1 or more claims may be submitted after the filing date of the application, within such period and under such conditions, including the payment of a surcharge, as may be prescribed by the Director. Upon failure to submit the fee, oath or declaration, and 1 or more claims within such prescribed period, the application shall be regarded as abandoned.

(4) FILING DATE.—The filing date of an application shall be the date on which a specification, with or without claims, is received in the United States Patent and Trademark Office.

#### (b) PROVISIONAL APPLICATION.—

(1) AUTHORIZATION.—A provisional application for patent shall be made or authorized to be made by the inventor, except as otherwise provided in this title, in writing to the Director. Such application shall include—

- (A) a specification as prescribed by [section 112\(a\)](#); and
- (B) a drawing as prescribed by [section 113](#).

(2) CLAIM.—A claim, as required by subsections (b) through (e) of [section 112](#), shall not be required in a provisional application.

(3) FEE.—The application shall be accompanied by the fee required by law. The fee may be submitted after the filing

date of the application, within such period and under such conditions, including the payment of a surcharge, as may be prescribed by the Director. Upon failure to submit the fee within such prescribed period, the application shall be regarded as abandoned.

(4) FILING DATE.—The filing date of a provisional application shall be the date on which a specification, with or without claims, is received in the United States Patent and Trademark Office.

(5) ABANDONMENT.—Notwithstanding the absence of a claim, upon timely request and as prescribed by the Director, a provisional application may be treated as an application filed under subsection (a). Subject to [section 119\(e\)\(3\)](#), if no such request is made, the provisional application shall be regarded as abandoned 12 months after the filing date of such application and shall not be subject to revival after such 12-month period.

(6) OTHER BASIS FOR PROVISIONAL APPLICATION.—Subject to all the conditions in this subsection and [section 119\(e\)](#) of this title, and as prescribed by the Director, an application for patent filed under subsection (a) may be treated as a provisional application for patent.

(7) NO RIGHT OF PRIORITY OR BENEFIT OF EARLIEST FILING DATE.—A provisional application shall not be entitled to the right of priority of any other application under [section 119](#), [365\(a\)](#), or [386\(a\)](#) or to the benefit of an earlier filing date in the United States under [section 120](#), [121](#), [365\(c\)](#), or [386\(c\)](#).

(8) APPLICABLE PROVISIONS.—The provisions of this title relating to applications for patent shall apply to provisional applications for patent, except as otherwise provided, and except that provisional applications for patent shall not be subject to [sections 131](#) and [135](#).

(c) PRIOR FILED APPLICATION.—Notwithstanding the provisions of subsection (a), the Director may prescribe the conditions, including the payment of a surcharge, under which a reference made upon the filing of an application under subsection (a) to a previously filed application, specifying the previously filed application by application number and the intellectual property authority or country in which the application was filed, shall constitute the specification and any drawings of the subsequent application for purposes of a filing date. A copy of the specification and any drawings of the previously filed application shall be submitted within such period and under such conditions as may be prescribed by the Director. A failure to submit the copy of the specification and any drawings of the previously filed application within the prescribed period shall result in the application being regarded as abandoned. Such application shall be treated as having never been filed, unless—

(1) the application is revived under [section 27](#); and

(2) a copy of the specification and any drawings of the previously filed application are submitted to the Director.

### 35 U.S.C. 111 (pre-PLT (AIA)) Application.

*[Editor Note: Applicable to any patent application filed on or after September 16, 2012, and before December 18, 2013. See [35 U.S.C. 111](#) or [pre-AIA 35 U.S.C. 111](#) for the law otherwise applicable.]*

Form paragraphs 6.63.01 and 6.63.02 may be used to notify applicant of corrections needed to comply with the requirements of [37 CFR 1.52\(e\)](#) and [37 CFR 1.58\(c\)](#) *et seq.* with respect to tables.

**¶ 6.63.01 Table Less Than 51 Pages Submitted Only as Text File**

The description portion of this application contains a table consisting of less than fifty one (51) pages only in ASCII text format submitted either via the Office Electronic Filing System or on read-only optical disc. In accordance with [37 CFR 1.58\(c\)\(1\)](#), only a table of at least fifty one (51) pages may be submitted as an ASCII text file. Accordingly, applicant is required to cancel the references to the table in text format appearing in the specification on pages [1], file a paper version of the table in compliance with [37 CFR 1.52](#) or file a PDF version via EFS-Web, and change all appropriate references to the former table in text format to the newly added paper or PDF version of the table in the remainder of the specification.

**Examiner Note:**

1. This form paragraph must be used whenever a table on a read-only optical disc or submitted as a text file via the Patent Electronic System consisting of less than fifty one (51) pages as part of the descriptive portion of the specification is filed on or after September 8, 2000. See [MPEP § 608.05\(b\)](#).

2. In bracket 1, insert the range of page numbers of the specification which reference the table.

**¶ 6.63.02 Table Column/Row Relationship Not Maintained**

This application contains a table in ASCII text format submitted either via the Office Electronic Filing System or on read-only optical disc. “Large Tables” submitted as an ASCII text file in compliance with [37 CFR 1.58\(d\)\(1\)](#) must maintain the spatial orientation of the cell entries. The table submitted does not maintain the data within each table cell in its proper row/column alignment. The data is misaligned in the table as follows: [1]. Applicant is required to submit a replacement text file via the Office Electronic Filing System or on read-only optical disc with the table data properly aligned.

**Examiner Note:**

1. This form paragraph must be used whenever the data in a table cannot be accurately read because the data in the table cells do not maintain their row and column alignments.

2. In bracket 1, insert the area of the table that does not maintain the row and column alignments.

**608.05(c) Submissions of Biological Sequence Listings [R-07.2022]**

Applications disclosing nucleotide and/or amino acid sequences, as defined in [37 CFR 1.821\(a\)](#) for applications filed before July 1, 2022 or as defined in [37 CFR 1.831\(b\)](#) for applications filed on or after

July 1, 2022, are required to provide the biological sequence information in a sequence listing.

For applications filed before July 1, 2022, the sequence listing can be a “Sequence Listing” (as an ACSII plain text file in compliance with [37 CFR 1.821-1.824](#)) submission must be submitted via the USPTO patent electronic filing system or on read-only optical disc. See [MPEP §§ 2420 et seq.](#) for detailed information.

For applications filed on or after July 1, 2022, the sequence listing must be a “Sequence Listing XML” (as an XML file in compliance with [37 CFR 1.831-1.834](#)) submission can be submitted via the USPTO patent electronic filing system or on read-only optical disc. See [MPEP §§ 2412-2419](#) for detailed information.

**609 Information Disclosure Statement [R-07.2022]**

**37 CFR 1.97 Filing of information disclosure statement.**

(a) In order for an applicant for a patent or for a reissue of a patent to have an information disclosure statement in compliance with [§ 1.98](#) considered by the Office during the pendency of the application, the information disclosure statement must satisfy one of paragraphs (b), (c), or (d) of this section.

(b) An information disclosure statement shall be considered by the Office if filed by the applicant within any one of the following time periods:

(1) Within three months of the filing date of a national application other than a continued prosecution application under [§ 1.53\(d\)](#);

(2) Within three months of the date of entry of the national stage as set forth in [§ 1.491](#) in an international application;

(3) Before the mailing of a first Office action on the merits;

(4) Before the mailing of a first Office action after the filing of a request for continued examination under [§ 1.114](#); or

(5) Within three months of the date of publication of the international registration under Hague Agreement Article 10(3) in an international design application.

(c) An information disclosure statement shall be considered by the Office if filed after the period specified in paragraph (b) of this section, provided that the information disclosure statement is filed before the mailing date of any of a final action under [§ 1.113](#), a notice of allowance under [§ 1.311](#), or an action that otherwise closes prosecution in the application, and it is accompanied by one of:

(1) The statement specified in paragraph (e) of this section; or

(2) The fee set forth in [§ 1.17\(p\)](#).

(d) An information disclosure statement shall be considered by the Office if filed by the applicant after the period specified in paragraph (c) of this section, provided that the information disclosure statement is filed on or before payment of the issue fee and is accompanied by:

(1) The statement specified in paragraph (e) of this section; and

(2) The fee set forth in [§ 1.17\(p\)](#).

(e) A statement under this section must state either:

(1) That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

(2) That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in [§ 1.56\(c\)](#) more than three months prior to the filing of the information disclosure statement.

(f) No extensions of time for filing an information disclosure statement are permitted under [§ 1.136](#). If a *bona fide* attempt is made to comply with [§ 1.98](#), but part of the required content is inadvertently omitted, additional time may be given to enable full compliance.

(g) An information disclosure statement filed in accordance with this section shall not be construed as a representation that a search has been made.

(h) The filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in [§ 1.56\(b\)](#).

(i) If an information disclosure statement does not comply with either this section or [§ 1.98](#), it will be placed in the file but will not be considered by the Office.

**37 CFR 1.98 Content of information disclosure statement.**

(a) Any information disclosure statement filed under [§ 1.97](#) shall include the items listed in paragraphs (a)(1), (a)(2) and (a)(3) of this section.

(1) A list of all patents, publications, applications, or other information submitted for consideration by the Office. U.S. patents and U.S. patent application publications must be listed in a section separately from citations of other documents. Each page of the list must include:

(i) The application number of the application in which the information disclosure statement is being submitted;

(ii) A column that provides a space, next to each document to be considered, for the examiner's initials; and

(iii) A heading that clearly indicates that the list is an information disclosure statement.

(2) A legible copy of:

(i) Each foreign patent;

(ii) Each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office;

(iii) For each cited pending unpublished U.S. application, the application specification including the claims, and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion; and

(iv) All other information or that portion which caused it to be listed.

(3)(i) A concise explanation of the relevance, as it is presently understood by the individual designated in [§ 1.56\(c\)](#) most knowledgeable about the content of the information, of each patent, publication, or other information listed that is not in the English language. The concise explanation may be either separate from applicant's specification or incorporated therein.

(ii) A copy of the translation if a written English-language translation of a non-English-language document, or portion thereof, is within the possession, custody, or control of, or is readily available to any individual designated in [§ 1.56\(c\)](#).

(b)(1) Each U.S. patent listed in an information disclosure statement must be identified by inventor, patent number, and issue date.

(2) Each U.S. patent application publication listed in an information disclosure statement shall be identified by applicant, patent application publication number, and publication date.

(3) Each U.S. application listed in an information disclosure statement must be identified by the inventor, application number, and filing date.

(4) Each foreign patent or published foreign patent application listed in an information disclosure statement must be identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application.

(5) Each publication listed in an information disclosure statement must be identified by publisher, author (if any), title, relevant pages of the publication, date, and place of publication.

(c) When the disclosures of two or more patents or publications listed in an information disclosure statement are substantively cumulative, a copy of one of the patents or publications as specified in paragraph (a) of this section may be submitted without copies of the other patents or publications, provided that it is stated that these other patents or publications are cumulative.

(d) A copy of any patent, publication, pending U.S. application or other information, as specified in paragraph (a) of this section, listed in an information disclosure statement is required to be provided, even if the patent, publication, pending U.S. application or other information was previously submitted to, or cited by, the Office in an earlier application, unless:



(1) The earlier application is properly identified in the information disclosure statement and is relied on for an earlier effective filing date under [35 U.S.C. 120](#); and

(2) The information disclosure statement submitted in the earlier application complies with paragraphs (a) through (c) of this section.

Information Disclosure Statements (IDSs) are not permitted in provisional applications filed under [35 U.S.C. 111\(b\)](#). See [37 CFR 1.51\(d\)](#). Since no substantive examination is given in provisional applications, a disclosure of information is unnecessary. Any such statement filed in a provisional application will be returned or destroyed at the option of the Office.

In nonprovisional applications, applicants and other individuals substantively involved with the preparation and/or prosecution of the application have a duty to submit to the Office information which is material to patentability as defined in [37 CFR 1.56](#). The provisions of [37 CFR 1.97](#) and [37 CFR 1.98](#) provide a mechanism by which patent applicants may comply with the duty of disclosure provided in [37 CFR 1.56](#) using an IDS. The IDS may be filed using form PTO/SB/08. Applicants and other individuals substantively involved with the preparation and/or prosecution of the patent application also may want the Office to consider information for a variety of other reasons; e.g., to make sure that the examiner has an opportunity to consider the same information that was considered by these individuals, or by another patent office in a counterpart or related patent application filed in another country.

Third parties (individuals not covered by [37 CFR 1.56\(c\)](#)) cannot file information disclosure statements under [37 CFR 1.97](#) and [37 CFR 1.98](#). Third parties may only submit patents and publications in compliance with [37 CFR 1.290](#) in applications published under [35 U.S.C. 122\(b\)](#). See [MPEP § 1134.01](#). For unpublished, pending applications, any member of the public, including private persons, corporate entities, and government agencies, may file a protest under [37 CFR 1.291](#) prior to the mailing of a notice of allowance under [37 CFR 1.311](#). See [MPEP Chapter 1900](#). Alternatively, third parties may provide information to the applicant who may submit the information to the Office in an IDS. See

[37 CFR 1.56\(d\)](#). The Office will review any submission in an application filed by a third party to determine whether the submission is in compliance with [37 CFR 1.290](#) or [1.291](#). Any third-party submission that does not comply with the requirements of [37 CFR 1.290](#) or [37 CFR 1.291](#) will not be entered into the application file and will be discarded. Office personnel (including the Patent Examining Corps) are instructed to: (1) not reply to or act upon any third-party inquiry or other submission in an application, except those in compliance with [37 CFR 1.290](#) or [37 CFR 1.291](#); and (2) decline to accept oral or telephone comments or submissions about applications from third parties. See [MPEP § 1134.01](#).

An information disclosure statement filed in accordance with the provisions of [37 CFR 1.97](#) and [37 CFR 1.98](#) will be considered by the examiner assigned to the application. Individuals associated in a substantive way with the filing and prosecution of a patent application are encouraged to submit information to the Office so the examiner can evaluate its relevance to the claimed invention. The procedures for submitting an information disclosure statement under the rules are designed to encourage individuals to submit information to the Office promptly and in a uniform manner. These rules provide certainty for the public by defining the requirements for submitting information disclosure statements to the Office so that the Office will consider information contained therein before a patent is granted.

The filing of an information disclosure statement shall not be construed as a representation that a search has been made. [37 CFR 1.97\(g\)](#). There is no requirement that an applicant for a patent make a patentability search. Further, the filing of an information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in [37 CFR 1.56\(b\)](#). [37 CFR 1.97\(h\)](#). See [MPEP § 2129](#) regarding admissions by applicant.

In order to have information considered by the Office during the pendency of a patent application, an information disclosure statement must be (1) in compliance with the content requirements of [37 CFR](#)

[1.98](#), (2) filed in accordance with the procedural requirements of [37 CFR 1.97](#) and (3) signed in compliance with [37 CFR 1.33\(b\)](#) (e.g., a separate signed page which references and accompanies the IDS). An e-IDS submission in compliance with the Legal Framework for Patent Electronic System ([MPEP § 502.03](#)) would satisfy the signature requirement. The requirements as to content are discussed in [MPEP § 609.04\(a\)](#). The requirements based on the time of filing the statement are discussed in [MPEP § 609.04\(b\)](#). Examiner handling of information disclosure statements is discussed in [MPEP § 609.05](#). For discussion of IDS filed electronically (e-IDS) via the USPTO patent electronic filing system, see [MPEP § 609.07](#). For discussion of electronic processing of IDS, see [MPEP § 609.08](#).

Once the minimum requirements of [37 CFR 1.97](#), [37 CFR 1.98](#), and [37 CFR 1.33\(b\)](#) are met, the examiner has an obligation to consider the information. There is no requirement that the information must be prior art references in order to be considered by the examiner. Consideration by the examiner of the information submitted in an IDS means nothing more than considering the documents in the same manner as other documents in Office search files are considered by the examiner while conducting a search of the prior art in a proper field of search. The initials of the examiner placed adjacent to the citations on the PTO/SB/08 or its equivalent mean that the information has been considered by the examiner to the extent noted above. In addition, the following alternative electronic signature method may be used by examiners in information disclosure statements to indicate whether the information has been considered. Examiners will no longer initial each reference citation considered, but will continue to strikethrough each citation not considered. Each page of reference citations will be stamped by the examiner with the phrase “All references considered except where lined through” along with the examiner’s electronic initials, and the final page of reference citations will include the examiner’s electronic signature. Information submitted to the Office that does not comply with the requirements of [37 CFR 1.97](#), [37 CFR 1.98](#), and [37 CFR 1.33\(b\)](#) will not be considered by the Office but will be placed in the application file.

Multiple information disclosure statements may be filed in a single application, and they will be considered, provided each is in compliance with the appropriate requirements of [37 CFR 1.97](#), [37 CFR 1.98](#) and [37 CFR 1.33\(b\)](#). Use of form PTO/SB/08, “Information Disclosure Statement,” is encouraged as a means to provide the required list of information as set forth in [37 CFR 1.98\(a\)\(1\)](#). Applicants are encouraged to use the USPTO form PTO/SB/08 when preparing an information disclosure statement because this form is updated by the Office. The form PTO/SB/08 will enable applicants to comply with the requirement to list each item of information being submitted and to provide the Office with a uniform listing of citations and with a ready way to indicate that the information has been considered. A copy of form PTO/SB/08 is reproduced at the end of this section.

**609.01 Examiner Checklist for Information Disclosure Statements [R-07.2022]**

Examiners must check to see if an information disclosure statement (IDS) complies with:

(A) All the time-related requirements of [37 CFR 1.97](#), which are based on the time of the filing of the IDS. See [MPEP § 609.04\(b\)](#) for more information.

<b><u>Time when IDS is filed</u></b>	<b><u>37 CFR 1.97 Requirements</u></b>
(1)(a) for national applications (not including CPAs), within three months of filing or before first Office action on the merits, whichever is later; (b) for national stage applications, within three months of entry into national stage or before first Office action on the merits, whichever is later; (c) for RCEs and CPAs before the first Office action on the merits; or (d) for international design applications, within three months of the date of publication of the international registration under Hague Agreement Article 10(3) or	None

<b>Time when IDS is filed</b>	<b><a href="#">37 CFR 1.97 Requirements</a></b>
before first Office action on the merits, whichever is later.	
(2) After (1) but before final action, notice of allowance, or <i>Quayle</i> action	<a href="#">1.97(e)</a> statement or <a href="#">1.17(p)</a> fee.
(3) After (2) and before (or with) payment of issue fee.	<a href="#">1.97(e)</a> statement, and <a href="#">1.17(p)</a> fee.
(4) After payment of issue fee.	IDS will not be considered.

(B) All content requirements of [37 CFR 1.98](#). See [MPEP § 609.04\(a\)](#) for more information.

(1) Requirements for the IDS listing:

(a) A separate section for citations of U.S. patents and U.S. patent application publications;

(b) The application number of the application in which the IDS is being submitted on each page of the listing, if known;

(c) A column that provides a blank space next to each citation for the examiner's initials when the examiner considers the cited document; and

(d) A heading on the listing that clearly indicates that the list is an Information Disclosure Statement;

(e) Proper identification of all cited references:

(i) U.S. patents cited by patent number, issue date and inventor(s);

(ii) U.S. patent application publications cited by publication number, publication date and inventor(s);

(iii) Pending U.S. applications cited by application number, filing date and inventor(s);

(iv) Foreign patent documents cited by document number, country and publication or issue date; and

(v) Non-patent literature cited by publisher, author (if any), title, relevant pages (when no page numbers are supplied, it is understood that all of the pages of the publication are the relevant pages), and date and place of publication.

(2) The requirement of copies for:

(a) Each cited foreign patent document;

(b) Each cited non-patent literature publication, or the portion therein which caused it to be listed;

(c) Each cited U.S. pending application that is not stored in IFW;

(d) All information cited (e.g., an affidavit or Office action), other than the specification, including claims and drawings, of a pending U.S. application; and

(e) All other cited information or the portion which caused it to be listed.

(3) For non-English documents that are cited, the following must be provided:

(a) A concise explanation of the relevance, as it is presently understood by the individual designated in [37 CFR 1.56\(c\)](#) most knowledgeable about the content of the information, unless a complete translation is provided; and/or

(b) A written English language translation of a non-English language document, or portion thereof, if it is within the possession, custody or control of, or is readily available to any individual designated in [37 CFR 1.56\(c\)](#).

After the examiner reviews the IDS for compliance with [37 CFR 1.97](#) and [1.98](#) (see [MPEP § 609.05](#)), the examiner should:

(A) Consider the information properly submitted in an IDS in the same manner that the examiner considers other documents in Office search files while conducting a search of the prior art in a proper field of search.

(1) For e-IDS, use the e-IDS icon on examiner's workstation to consider cited U.S. patents and U.S. patent application publications. See [MPEP § 609.07](#) for more information on e-IDS.

(2) Initial the blank column next to the citation to indicate that the information has been considered by the examiner, or use the alternative electronic signature method by inserting on each page of reference citations the phrase "All references considered except where lined through" along with the examiner's electronic initials, and providing the examiner's electronic signature on the final page of reference citations.



(B) Draw a line through the citation to show that it has not been considered if the citation fails to comply with all the requirements of [37 CFR 1.97](#) and [37 CFR 1.98](#). The examiner should inform applicant the reasons why a citation was not considered. If a *bona fide* attempt is made to comply with the content requirements of [37 CFR 1.98](#), but part of the required content is inadvertently omitted, additional time may be given to enable full compliance pursuant to [37 CFR 1.97\(f\)](#). See [MPEP § 609.04\(b\)](#), subsection VI and form paragraph 6.51.

(C) Write “not considered” on an information disclosure statement if none of the information listed complies with the requirements of [37 CFR 1.97](#) and [37 CFR 1.98](#). The examiner will inform applicant the reasons why the IDS was not considered by using form paragraphs 6.49 through 6.49.10.

(D) Sign and date the bottom of the IDS listing, or use the alternative electronic signature method noted in item (A)(2) above.

(E) Ensure that a copy of the IDS listing that is signed and dated by the examiner is entered into the file and mailed to applicant.

For discussion of electronic processing of IDS, see [MPEP § 609.08](#).

## **609.02 Information Disclosure Statements in Continued Examinations or Continuing Applications [R-07.2015]**

### **I. CONSIDERATION OF PRIOR ART CITED IN A PARENT INTERNATIONAL APPLICATION**

When filing a continuing application that claims benefit under [35 U.S.C. 120](#) to a parent application (other than an international application that designated the U.S.), it will not be necessary for the applicant to submit an information disclosure statement in the continuing application that lists the prior art cited by the examiner in the parent application unless the applicant desires the information to be printed on the patent issuing from the continuing application (for continued prosecution applications filed under [37 CFR 1.53\(d\)](#), see subsection A.1. below). The examiner of the continuing application will consider information which has been considered by the Office in the parent application.

When filing a continuing application that claims benefit under [35 U.S.C. 120](#) to an international application that designated the U.S. (see [MPEP § 1895](#)), it will be necessary for the applicant to submit an information disclosure statement complying with [37 CFR 1.97](#) and [1.98](#) in the continuing application listing the documents cited in the international search report and/or the international preliminary examination report of the international application if applicant wishes to ensure that the information is considered by the examiner in the continuing application.

See [MPEP § 609.03](#) for consideration of documents cited in the international search report in a PCT national stage application.

### **II. IDS IN CONTINUED EXAMINATIONS OR CONTINUING APPLICATIONS**

#### ***A. IDS That Has Been Considered (1) in the Parent Application, or (2) Prior to the Filing of a Request for Continued Examination (RCE)***

##### **1. Continued Prosecution Applications (CPAs) Filed Under 37 CFR 1.53(d)**

Information which has been considered by the Office in the parent application of a continued prosecution application (CPA) filed under [37 CFR 1.53\(d\)](#) will be part of the file before the examiner and need not be resubmitted in the continuing application to have the information considered and listed on the patent.

##### **2. Continuation Applications, Divisional Applications, or Continuation-in-Part Applications Filed Under 37 CFR 1.53(b)**

The examiner will consider information which has been considered by the Office in a parent application (other than an international application; see subsection I., above) when examining: (A) a continuation application filed under [37 CFR 1.53\(b\)](#), (B) a divisional application filed under [37 CFR 1.53\(b\)](#), or (C) a continuation-in-part application filed under [37 CFR 1.53\(b\)](#). A listing of the information need not be resubmitted in the

continuing application unless the applicant desires the information to be printed on the patent.

If resubmitting a listing of the information, applicant should submit a new listing that complies with the format requirements in [37 CFR 1.98\(a\)\(1\)](#) and the timing requirements of [37 CFR 1.97](#). Applicants are strongly discouraged from submitting a list that includes copies of PTO/SB/08 or PTO-892 forms from other applications. A completed PTO/SB/08 form from another application may already have initials of an examiner and the application number of another application. This information will likely confuse the record. Furthermore, when the spaces provided on the form have initials of an examiner, there are no spaces available next to the documents listed for the examiner of the subsequent application to provide his or her initials, and the previously relevant initials may be erroneously construed as being applied for the current application.

### **3. Requests for Continued Examination (RCE) Under 37 CFR 1.114**

Information which has been considered by the Office in the application before the filing of a RCE will be part of the file before the examiner and need not be resubmitted to have the information considered by the examiner and listed on the patent.

#### ***B. IDS That Has Not Been Considered (1) in the Parent Application, or (2) Prior to the Filing of a Request for Continued Examination***

#### **1. Continued Prosecution Applications Filed Under 37 CFR 1.53(d)**

Information filed in the parent application that complies with the content requirements of [37 CFR 1.98](#) will be considered by the examiner in the CPA. No specific request from the applicant that the previously submitted information be considered by the examiner is required.

#### **2. Continuation Applications, Divisional Applications, or Continuation-In-Part Applications Filed Under 37 CFR 1.53(b)**

For these types of applications, in order to ensure consideration of information previously submitted, but not considered, in a parent application, applicant must resubmit the information in the continuing application in compliance with [37 CFR 1.97](#) and [37 CFR 1.98](#). Pursuant to [37 CFR 1.98\(d\)](#), if the IDS submitted in the parent application complies with [37 CFR 1.98\(a\)](#) to [\(c\)](#), copies of the patents, publications, pending U.S. applications, or other information submitted in the parent application need not be resubmitted in the continuing application.

When resubmitting a listing of the information, applicant should submit a new listing that complies with the format requirements in [37 CFR 1.98\(a\)\(1\)](#). Applicants are strongly discouraged from submitting a list that includes copies of PTO/SB/08 or PTO-892 forms from other applications. A PTO/SB/08 form from another application may already have the application number of another application. This information will likely confuse the record.

#### **3. Requests for Continued Examination Under 37 CFR 1.114**

Information filed in the application in compliance with the content requirements of [37 CFR 1.98](#) before the filing of a RCE will be considered by the examiner after the filing of the RCE. For example, an applicant filed an IDS in compliance with [37 CFR 1.98](#) after the mailing of a final Office action, but the IDS did not comply with the requirements of [37 CFR 1.97\(d\)\(1\)](#) and [\(d\)\(2\)](#) and therefore, the IDS was not considered by the examiner. After applicant files a RCE, the examiner will consider the IDS filed prior to the filing of the RCE. For more details on RCE, see [MPEP § 706.07\(h\)](#).

### **609.03 Information Disclosure Statements in National Stage Applications [R-07.2022]**

When examining a PCT national stage application, the examiner will consider all U.S. patents, U.S. patent application publications, and U.S. pending applications cited in the international search report that are stored electronically in the USPTO's Image

File Wrapper (IFW) system. The examiner will consider other documents cited in the international search report when the Form PCT/DO/EO/903 in the national stage application indicates that both the international search report and the copies of the documents are present in the national stage file. In such a case, the examiner should consider the documents from the international search report and indicate by a statement in the first Office action that the information has been considered. There is no requirement that the examiner list the documents on a PTO-892 form and there is no requirement for the applicant to provide a separate listing of the references. However, the citations will not be printed on the face of the patent unless listed on a list that lends itself to easy capture of the necessary information by the Office printing contractor. See [MPEP § 609.06](#).

In a national stage application, the following form paragraphs may be used where appropriate to notify applicant regarding references listed in the search report of the international application:

**¶ 6.53 References Considered in 35 U.S.C. 371 Application Based Upon Search Report - Prior to Allowance**

The references cited in the PCT international search report by the [1] have been considered, but will not be listed on any patent resulting from this application because they were not provided on a separate list in compliance with [37 CFR 1.98\(a\)\(1\)](#). In order to have the references printed on such resulting patent, a separate listing, preferably on a PTO/SB/08 form, must be filed within the set period for reply to this Office action.

**Examiner Note:**

1. In bracket [1], identify the office (e.g., JPO, EPO, etc.) that issued the international search report and the date it issued.
2. This form paragraph may be used for national stage applications under [35 U.S.C. 371](#) where the examiner has obtained copies of the cited references or where copies of such references are not required under [37 CFR 1.98](#). If receipt of copies of references required under [37 CFR 1.98](#) is not indicated on the PCT/DO/EO/903 form in the file, burden is on the applicant to supply such copies for consideration. See [MPEP § 1893.03\(g\)](#).
3. Instead of using this form paragraph, the examiner may list the references on a PTO-892, thereby notifying the applicant that the references have been considered and will be printed on any patent resulting from this application.
4. This form paragraph should only be used prior to allowance when a statutory period for reply is being set in the Office action.
5. If the application is being allowed, form paragraph 6.54 should be used with the Notice of Allowability instead of this form paragraph.

**¶ 6.54 References Considered in 35 U.S.C. 371 Application Based Upon Search Report - Ready for Allowance**

The references cited in the PCT international search report by the [1] have been considered, but will not be listed on any patent resulting from this application because they were not provided on a separate list in compliance with [37 CFR 1.98\(a\)\(1\)](#). In order to have the references printed on such resulting patent, a separate listing, preferably on a PTO/SB/08 form, must be filed within ONE MONTH of the mailing date of this communication. NO EXTENSION OF TIME WILL BE GRANTED UNDER EITHER [37 CFR 1.136\(a\)](#) OR (b) to comply with this requirement.

**Examiner Note:**

1. In bracket [1], identify the office (e.g., JPO, EPO, etc.) that issued the international search report and the date it issued.
2. This form paragraph may be used for national stage applications under [35 U.S.C. 371](#) where the examiner has obtained copies of the cited references or where copies of such references are not required under [37 CFR 1.98](#). If receipt of copies of references required under [37 CFR 1.98](#) is not indicated on the PCT/DO/EO/903 form in the file, burden is on the applicant to supply such copies for consideration. See [MPEP § 1893.03\(g\)](#).
3. Instead of using this form paragraph, the examiner may list the references on a PTO-892, thereby notifying the applicant that the references have been considered and will be printed on any patent resulting from this application.

**¶ 6.55 References Not Considered in 35 U.S.C. 371 Application Based Upon Search Report**

The listing of references in the PCT international search report is not considered to be an information disclosure statement (IDS) complying with [37 CFR 1.98](#). [37 CFR 1.98\(a\)\(2\)](#) requires a legible copy of: (1) each foreign patent; (2) each publication or that portion which caused it to be listed; (3) for each cited pending U.S. application, the application specification including claims, and any drawing of the application, or that portion of the application which caused it to be listed including any claims directed to that portion, unless the cited pending U.S. application is stored in the Image File Wrapper (IFW) system; and (4) all other information, or that portion which caused it to be listed. In addition, each IDS must include a list of all patents, publications, applications, or other information submitted for consideration by the Office (see [37 CFR 1.98\(a\)\(1\)](#) and (b)), and [MPEP § 609.04\(a\)](#), subsection I. states, “the list ... must be submitted on a separate paper.” Therefore, the references cited in the international search report have not been considered. Applicant is advised that the date of submission of any item of information or any missing element(s) will be the date of submission for purposes of determining compliance with the requirements based on the time of filing the IDS, including all “statement” requirements of [37 CFR 1.97\(e\)](#). See [MPEP § 609.05\(a\)](#).

**Examiner Note:**

1. This form paragraph may be used in national stage applications under [35 U.S.C. 371](#).

2. Do not use this form paragraph when the missing references are U.S. patents, U.S. patent application publications, or U.S. pending applications that are stored in IFW.

## **609.04 Content and Timing Requirements for an Information Disclosure Statement [R-07.2022]**

### **609.04(a) Content Requirements for an Information Disclosure Statement [R-07.2022]**

An information disclosure statement (IDS) must comply with the provisions of [37 CFR 1.98](#) as to content for the information listed in the IDS to be considered by the Office. Each information disclosure statement must comply with the applicable provisions of subsection I., II., and III. below. If a *bona fide* attempt is made to comply with the content requirements of [37 CFR 1.98](#), but part of the required content is inadvertently omitted, additional time may be given to enable full compliance pursuant to [37 CFR 1.97\(f\)](#). See [MPEP § 609.04\(b\)](#), subsection VI and form paragraph 6.51.

#### **I. LIST OF ALL PATENTS, PUBLICATIONS, U.S. APPLICATIONS, OR OTHER INFORMATION**

Each information disclosure statement must include a list of all patents, publications, U.S. applications, or other information submitted for consideration by the Office.

[37 CFR 1.98\(a\)\(1\)](#) requires the following format for an IDS listing: (A) a specified format/identification for each page of an IDS, and that U.S. patents and U.S. patent application publications be listed in a section separately from citations of other documents; (B) a column that provides a space next to each document listed to permit the examiner's initials; and (C) a heading that identifies the list as an IDS.

[37 CFR 1.98\(a\)\(1\)](#) specifically requires that U.S. patents and U.S. patent application publications be listed separately from the citations of other documents. The separation of citations will permit the Office to obtain the U.S. patent numbers and the U.S. patent application publication numbers by optical character recognition (OCR) from the

scanned documents such that the documents can be made available electronically to the examiner to facilitate searching and retrieval of the cited U.S. patents and U.S. patent application publications from the Office's search databases. Applicants will comply with this requirement if they use forms PTO/SB/08, which provide a separate section for listing U.S. patents and U.S. patent application publications. Applicants who do not use these forms for submitting an IDS must make sure that the U.S. patents and U.S. patent application publications are listed in a separate section from citations of other documents.

[37 CFR 1.98\(a\)\(1\)](#) also requires that each page of the list must clearly identify the application number of the application in which the IDS is being submitted, if known. In the past, the Office has experienced problems associated with lists that do not properly identify the application in which the IDS is being submitted (e.g., when applicants submit a list that includes copies of PTO/SB/08 or PTO-892 forms from other applications). Even though the IDS cover sheet had the proper application number, each page of the list did not include the proper application number, but instead had the application numbers of the other applications. If the pages of the list became separated, the Office could not associate the pages with the proper application.

In addition, [37 CFR 1.98\(a\)\(1\)](#) requires that the list must include a column that provides a space next to each document listed in order to permit the examiner to enter their initials next to the citations of the documents that have been considered by the examiner. This provides a notification to the applicant and a clear record in the application to indicate which documents have been considered by the examiner in the application. Applicants are strongly discouraged from submitting a list that includes copies of PTO/SB/08 or PTO-892 forms from other applications. A completed PTO/SB/08 form from another application may already have initials of an examiner and the application number of another application. This information will likely confuse the record. Furthermore, when the spaces provided on the form have initials of an examiner, there are no spaces available next to the documents listed for the examiner of the subsequent application to provide their initials, and the previously relevant



initials may be erroneously construed as being applied for the current application.

[37 CFR 1.98\(a\)\(1\)](#) also requires that each page of the list include a heading that clearly indicates that the list is an IDS. Since the Office treats an IDS submitted by the applicant differently than information submitted by a third party, a heading on each page of the list to indicate that the list is an IDS would promote proper treatment of the IDS submitted by the applicant and reduce handling errors.

[37 CFR 1.98\(b\)](#) requires that each item of information in an IDS be identified properly. U.S. patents must be identified by the inventor, patent number, and issue date. U.S. patent application publications must be identified by the applicant, patent application publication number, and publication date. The Office will also accept a citation in an IDS where a U.S. patent application publication is identified using the inventor instead of the applicant. U.S. applications must be identified by the inventor, the eight digit application number (the two digit series code and the six digit serial number), and the filing date. If a U.S. application being listed in an IDS has been issued as a patent or has been published, the applicant should list the patent or application publication in the IDS instead of the application. Each foreign patent or published foreign patent application must be identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application. Each publication must be identified by publisher, author (if any), title, relevant pages of the publication, and date and place of publication. When no page numbers are supplied, it is understood that all of the pages of the publication are the relevant pages. The date of publication supplied must include at least the month and year of publication, except that the year of publication (without the month) will be accepted if the applicant points out in the information disclosure statement that the year of publication is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the particular month of publication is not in issue. The place of publication refers to the name of the journal, magazine, or other publication in which the information being submitted

was published. See [MPEP § 707.05\(e\)](#), for more information on data that should be used when citing publications and electronic documents.

Pending U.S. applications that are being cited can be listed under the non-patent literature section or in a new section appropriately labeled. If applicant seeks consideration of documents other than the specification (including the claims) and drawings of an application, for example, Office actions, applicant must list such documents separately under the non-patent literature section or in a new section appropriately labeled. The USPTO would be understood to be the publisher/place of publication for a listed U.S. Office action or a U.S. application. Similarly, the foreign or international entity (*e.g.*, WIPO, EPO) would be understood to be the publisher/place of publication for a listed foreign or international search report.

For publications obtained from the internet, the uniform resource locator (URL) of the webpage that is the source of the publication must be provided for the place of publication (*e.g.*, "www.uspto.gov"). The publisher may be evident from the URL of the webpage. See [MPEP § 707.05\(e\)](#) for examples on listing documents retrieved from the internet, including social media posts and screen shots from videos. In particular, see examples 17 and 18. Further, for an internet publication obtained from a website that archives webpages, both the URL of the archived webpage submitted for consideration and the URL of the website from which the archived copy of the webpage was obtained should be provided on the document listing (*e.g.*, "Hand Tools , " w e b p a g e <<http://www.farmshopstore.com/handtools.html>>, 1 page, August 18, 2009, retrieved from Internet Archive Wayback Machine <<http://web.archive.org/web/20090818144217/http://www.farmshopstore.com/handtools.html>> on December 20, 2012). Where the actual publication date of a non-patent document is not known, the applicant must, at a minimum, provide a date of retrieval (*e.g.*, the date a webpage was retrieved) or a time frame (*e.g.*, a year, a month and year, a certain period of time ) when the document was available as a publication.



The list of information complying with the format requirements of [37 CFR 1.98\(a\)\(1\)](#) and the identification requirements of [37 CFR 1.98\(b\)](#) may not be incorporated into the specification of the application in which it is being supplied, but must be submitted in a separate paper. A separate list is required so that it is easy to confirm that applicant intends to submit an information disclosure statement and because it provides a readily available checklist for the examiner to indicate which identified documents have been considered. A separate list will also provide a simple means of communication to applicant to indicate the listed documents that have been considered and those listed documents that have not been considered. Use of form PTO/SB/08, Information Disclosure Statement, to list the documents is encouraged.

## II. LEGIBLE COPIES

In addition to the list of information, each information disclosure statement must also include a legible copy of:

(A) Each foreign patent;

(B) Each publication or that portion which caused it to be listed, other than U.S. patents and U.S. patent application publications unless required by the Office;

(C) For each cited pending unpublished U.S. application, the application specification including the claims, and any drawings of the application, or that portion of the application which caused it to be listed including any claims directed to that portion, unless the cited pending U.S. application is stored in the Image File Wrapper (IFW) system. The requirement in [37 CFR 1.98\(a\)\(2\)\(iii\)](#) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is *sua sponte* waived where the cited pending application is stored in the USPTO's IFW system. *See Waiver of the Copy Requirement in 37 CFR 1.98 for Cited Pending U.S. Patent Applications*, 1287 OG 163 (October 19, 2004); and

(D) All other information or that portion which caused it to be listed.

There is no requirement for a copy of each U.S. patent or U.S. patent application publication listed in an IDS unless required by the Office. [37 CFR 1.98\(a\)\(2\)](#).

[37 CFR 1.98\(a\)\(2\)\(iii\)](#) requires a copy of a pending U.S. application that is being cited in an IDS if (A) the cited information is not part of the specification, including the claims, and the drawings (e.g., an Office Action, remarks in an amendment paper, etc.), or (B) the cited application is not stored in the USPTO's IFW system. The requirement in [37 CFR 1.98\(a\)\(2\)\(iii\)](#) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is *sua sponte* waived where the cited pending application is stored in the USPTO's IFW system. This waiver is limited to the specification, including the claims, and drawings in the U.S. application (or portion of the application). If material other than the specification, including the claims, and drawings in the file of a U.S. patent application is being cited in an IDS, the IDS must contain a legible copy of such material.

A pending U.S. application only identified in the specification's background information rather than being cited separately on an IDS listing is not part of an IDS submission. Therefore, the requirements of [37 CFR 1.98\(a\)\(2\)\(iii\)](#) of supplying a copy of the pending application is not applicable. Pursuant to [37 CFR 1.98\(a\)\(2\)\(iii\)](#), applicant may choose to cite only a portion of a pending application including any claims directed to that portion rather than the entire application. There are exceptions to this requirement that a copy of the information must be provided. First, [37 CFR 1.98\(d\)](#) states that a copy of any patent, publication, pending U.S. application, or other information listed in an information disclosure statement is not required to be provided if: (A) the information was previously cited by or submitted to, the Office in a prior application, provided that the prior application is properly identified in the IDS and is relied on for an earlier filing date under [35 U.S.C. 120](#); and (B) the IDS submitted in the earlier application complies with [37 CFR 1.98\(a\)-\(c\)](#). If both of these conditions are met, the examiner will consider the information previously cited or submitted to the Office and

considered by the Office in a prior application relied on under [35 U.S.C. 120](#). This exception to the requirement for copies of information does not apply to information which was cited in an international application under the Patent Cooperation Treaty. If the information cited or submitted in the prior application was not in English, a concise explanation of the relevance of the information to the new application is not required unless the relevance of the information differs from its relevance as explained in the prior application. See subsection III. below.

Second, [37 CFR 1.98\(c\)](#) states that when the disclosures of two or more patents or publications listed in an information disclosure statement are substantively cumulative, a copy of one of the patents or publications may be submitted without copies of the other patents or publications provided that a statement is made that these other patents or publications are cumulative. The examiner will then consider only the patent or publication of which a copy is submitted and will so indicate on the list, form PTO/SB/08, submitted, e.g., by crossing out the listing of the cumulative information. But see *Semiconductor Energy Laboratory Co. v. Samsung Electronics Co.*, 204 F.3d 1368, 1374, 54 USPQ2d 1001, 1005 (Fed. Cir. 2000) (Reference was not cumulative since it contained a more complete combination of the claimed elements than any other reference before the examiner. “A withheld reference may be highly material when it discloses a more complete combination of relevant features, even if those features are before the patent examiner in other references.” (citations omitted).).

[37 CFR 1.98\(a\)\(3\)\(ii\)](#) states that if a written English language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in [37 CFR 1.56\(c\)](#), a copy of the translation shall accompany the statement. Translations are not required to be filed unless they have been reduced to writing and are actually translations of what is contained in the non-English language information. If no translation is submitted, the examiner will consider the information in view of the concise explanation and insofar as it is understood on its face, e.g., drawings, chemical formulas, English language abstracts, in

the same manner that non-English language information in Office search files is considered by examiners in conducting searches.

Electronic means or medium for filing IDSs are not permitted except for: (A) IDSs electronically submitted using the USPTO patent electronic filing system (see [MPEP § 609.07](#)); or (B) copies of large tables, computer program listings, and sequence listings submitted as a PDF file and a “Sequence Listing XML” submitted as an XML file on a read-only optical disc in compliance with [37 CFR 1.52\(e\)\(2\)](#) and [\(3\)](#) which are cited in a paper IDS. A read-only optical disc cannot be used to submit an IDS listing or copies of the documents cited in the IDS (except for large tables, a computer program listing, a sequence listing, and a “Sequence Listing XML”, discussed above). For example, published information, such as the visual output of a software program or a video, may be submitted only if reduced to writing, such as in the form of screen shots and/or a transcript.

### III. CONCISE EXPLANATION OF RELEVANCE FOR NON-ENGLISH LANGUAGE INFORMATION

Each information disclosure statement must further include a concise explanation of the relevance, as it is presently understood by the individual designated in [37 CFR 1.56\(c\)](#) most knowledgeable about the content of the information listed that is not in the English language. The concise explanation may be either separate from the specification or part of the specification. If the concise explanation is part of the specification, the IDS listing should include the page(s) or line(s) numbers where the concise explanation is located in the specification.

The requirement for a concise explanation of relevance is limited to information that is not in the English language. The explanation required is limited to the relevance as understood by the individual designated in [37 CFR 1.56\(c\)](#) most knowledgeable about the content of the information at the time the information is submitted to the Office. If a complete translation of the information into English is submitted with the non-English language information, no concise explanation is required. There is no requirement for the translation to be verified, including reliable machine translations. An

English-language equivalent application may be submitted to fulfill this requirement if it is, in fact, a translation of a foreign language application being listed in an information disclosure statement. The English language equivalent application should be separately listed and identified as an English language equivalent in the information disclosure statement. Submission of an English language abstract of a reference, such as one generated by a foreign patent office, may fulfill the requirement for a concise explanation. Where the information listed is not in the English language, but was cited in a search report or other action by a foreign patent office in a counterpart foreign application, the requirement for a concise explanation of relevance can be satisfied by submitting an English-language version of the search report or action which indicates the degree of relevance found by the foreign office. This may be an explanation of which portion of the reference is particularly relevant, to which claims it applies, or merely an “X”, “Y”, or “A” indication on a search report. The requirement for a concise explanation of non-English language information would not be satisfied by a statement that a reference was cited in the prosecution of a United States application which is not relied on under [35 U.S.C. 120](#).

If information cited or submitted in a prior application relied on under [35 U.S.C. 120](#) was not in English, a concise explanation of the relevance of the information to the new application is not required unless the relevance of the information differs from its relevance as explained in the prior application.

The concise explanation may indicate that a particular figure or paragraph of the patent or publication is relevant to the claimed invention. It might be a simple statement pointing to similarities between the item of information and the claimed invention. It is permissible but not necessary to discuss differences between the cited information and the claims. However, see *Semiconductor Energy Laboratory Co. v. Samsung Electronics Co.*, 204 F.3d 1368, 1376, 54 USPQ2d 1001, 1007 (Fed. Cir. 2000) (“[A]lthough MPEP Section 609A(3) allows the applicant some discretion in the manner in which it phrases its concise explanation, it nowhere

authorizes the applicant to intentionally omit altogether key teachings of the reference.”).

In *Semiconductor Energy Laboratory*, patentee during prosecution submitted an untranslated 29-page Japanese reference as well as a concise explanation of its relevance and an existing one-page partial English translation, both of which were directed to less material portions of the reference. The untranslated portions of the Japanese reference “contained a more complete combination of the elements claimed [in the patent] than anything else before the PTO.” 204 F.3d at 1376, 54 USPQ2d at 1005. The patentee, whose native language was Japanese, was held to have understood the materiality of the reference. “The duty of candor does not require that the applicant translate every foreign reference, but only that the applicant refrain from submitting partial translations and concise explanations that it knows will misdirect the examiner’s attention from the reference’s relevant teaching.” 204 F.3d at 1378, 54 USPQ2d at 1008.

Although a concise explanation of the relevance of the information is not required for English language information, applicants are encouraged to provide a concise explanation of why the English-language information is being submitted and how it is understood to be relevant. Concise explanations (especially those which point out the relevant pages and lines) are helpful to the Office, particularly where documents are lengthy and complex and applicant is aware of a section that is highly relevant to patentability or where a large number of documents are submitted and applicant is aware that one or more are highly relevant to patentability.

#### **609.04(b) Timing Requirements for an Information Disclosure Statement [R-07.2022]**

The procedures and requirements under [37 CFR 1.97](#) for submitting an information disclosure statement are linked to four stages in the processing of a patent application:

(1)(a) for national applications (not including CPAs), within three months of filing, or before the mailing of a first Office action on the merits, whichever is later;

(b) for international applications, within three months of the date of entry of the national stage as set forth in [37 CFR 1.491](#) or before the mailing of a first Office action on the merits in the national stage application, whichever is later;

(c) for continued examinations (i.e., RCEs filed under [37 CFR 1.114](#)) and CPAs filed under [37 CFR 1.53\(d\)](#), before the mailing of a first Office action on the merits;

(d) for international design applications, within three months of the date of publication of the international registration under Hague Agreement Article 10(3) or before first Office action on the merits, whichever is later;

(2) after the period in (1), but prior to the prosecution of the application closes, i.e., before the mailing of a final Office action, a Notice of Allowance, or an *Ex parte Quayle* action, whichever is earlier;

(3) after the period in (2) but on or before the date the issue fee is paid; and

(4) after the period in (3) and up to the time the patent application can be effectively withdrawn from issue under [37 CFR 1.313\(c\)](#).

These procedures and requirements apply to applications filed under [35 U.S.C. 111\(a\)](#) (utility), [161](#) (plants), [171](#) (designs), and [251](#) (reissue), as well as international applications entering the national stage under [35 U.S.C. 371](#).

The requirements based on the time when the information disclosure statement is filed are summarized in [MPEP § 609.01](#).

**I. INFORMATION DISCLOSURE STATEMENT FILED BEFORE FIRST ACTION ON THE MERITS OR WITHIN THREE (3) MONTHS OF ACTUAL FILING DATE, NATIONAL STAGE ENTRY DATE, OR PUBLICATION UNDER ARTICLE 10(3) OF THE HAGUE AGREEMENT (37 CFR 1.97(b))**

An information disclosure statement will be considered by the examiner if filed within any one of the following time periods:

(A) for national applications (not including CPAs), within three months of the filing date of the national application or before the mailing date of a first Office action on the merits;

(B) for international applications, within three months of the date of entry of the national stage as set forth in [37 CFR 1.491](#) or before the mailing date of a first Office action on the merits;

(C) for RCEs and CPAs, before the mailing date of a first Office action on the merits; or

(D) for international design applications, within three months of the date of publication of the international registration under Hague Agreement Article 10(3) or before first Office action on the merits, whichever is later

An information disclosure statement filed within one of these periods requires neither a fee nor a statement under [37 CFR 1.97\(e\)](#). An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of mailing if accompanied by a properly executed certificate of mailing or facsimile transmission under [37 CFR 1.8](#), or if it is in compliance with the provisions of Priority Mail Express® delivery under [37 CFR 1.10](#). If the last day of the three months period set forth in [37 CFR 1.97\(b\)\(1\)](#) and [\(b\)\(2\)](#) falls on a Saturday, Sunday, or a federal holiday within the District of Columbia, the IDS may be timely filed on the next succeeding business day which is not a Saturday, Sunday, or a federal holiday. See [37 CFR 1.7\(a\)](#). An Office action is mailed on the date indicated in the Office action.

It would not be proper to make final a first Office action in a continuing application or in an application after the filing of an RCE if the information submitted in the IDS during the time period set forth in [37 CFR 1.97\(b\)](#) is used in a new ground of rejection.

**A. National Applications, International Applications, and International Design Applications**

The term “national application” includes continuing applications (continuations, divisions, and continuations-in-part but not CPAs), so three months will be measured from the actual filing date of an application as opposed to the effective filing date of a continuing application. For international applications, the three months will be measured from the date of entry of the national stage. For international design applications, the three months will be measured from the date of publication of the



international registration under Hague Agreement Article 10(3).

All information disclosure statements that comply with the content requirements of [37 CFR 1.98](#) and are filed within three months of the filing date, will be considered by the examiner, regardless of whatever else has occurred in the examination process up to that point in time. Thus, in the rare instance that a final Office action, a notice of allowance, or an *Ex parte Quayle* action is mailed prior to a date which is three months from the filing date, any information contained in a complete information disclosure statement filed within that three-month window will be considered by the examiner.

Likewise, an information disclosure statement will be considered if it is filed later than three months after the application filing date but before the mailing date of a first Office action on the merits. An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirement ([37 CFR 1.142](#)) or just a requirement for additional fees to have a claim considered ([37 CFR 1.16](#)). Thus, if an application was filed on January 2 and the first Office action on the merits was not mailed until six months later on July 2, the examiner would be required to consider any proper information disclosure statement filed prior to July 2.

#### **B. RCE and CPA**

The three-month window as discussed above does not apply to a RCE filed under [37 CFR 1.114](#) or a CPA filed under [37 CFR 1.53\(d\)](#) (effective July 14, 2003, CPAs are only available for design applications). An IDS filed after the filing of a RCE will be considered if the IDS is filed before the mailing date of a first Office action on the merits. A RCE is not the filing of an application, but merely the continuation of prosecution in the current application. After the mailing of a RCE, such application is treated as an amended application by the examiner and is subject to a short turnover time. Therefore, applicants are encouraged to file any IDS

with the filing of a RCE. See [MPEP § 706.07\(h\)](#) for details on RCEs.

Similarly, an IDS filed in a CPA will be considered if the IDS is filed before the mailing date of a first Office action on the merits. Applicants are encouraged to file any IDS in a CPA as early as possible, preferably at the time of filing of the CPA request.

If an IDS cannot be filed before the mailing of a first Office action on the merits (generally within two months from the filing of the RCE or CPA), applicants may request a three-month suspension of action under [37 CFR 1.103\(c\)](#) in an application at the time of filing of the RCE, or under [37 CFR 1.103\(b\)](#) in a CPA, at the time of filing of the CPA. Where an IDS is mailed to the Office shortly before the expiration of a three-month suspension under [37 CFR 1.103\(b\)](#) or (c), applicant is requested to make a courtesy call to notify the examiner as to the IDS submission.

#### **II. INFORMATION DISCLOSURE FILED AFTER I. ABOVE BUT BEFORE MAILING OF FINAL ACTION, NOTICE OF ALLOWANCE, OR AN EX PARTE QUAYLE ACTION (37 CFR 1.97(c))**

An information disclosure statement will be considered by the examiner if filed after the period specified in subsection I. above, but prior to the date the prosecution of the application closes, i.e., before (not on the same day as the mailing date of any of the following):

a final action under [37 CFR 1.113](#), e.g., final rejection;

a notice of allowance under [37 CFR 1.311](#); or

an action that closes prosecution in the application, e.g., an *Ex parte Quayle* action,

whichever occurs first, provided the information disclosure statement is accompanied by either (1) a statement as specified in [37 CFR 1.97\(e\)](#) (see the discussion in subsection V below); or (2) the fee set forth in [37 CFR 1.17\(p\)](#). If a final action, notice of allowance, or an *Ex parte Quayle* action is mailed in an application and later withdrawn, the application



will be considered as not having had a final action, notice of allowance, or an *Ex parte Quayle* action mailed for purposes of considering an information disclosure statement.

An *Ex parte Quayle* action is an action that closes the prosecution in the application as referred to in [37 CFR 1.97\(c\)](#). Therefore, an information disclosure statement filed on the same day as or after the mailing date of an *Ex parte Quayle* action must comply with the provisions of [37 CFR 1.97\(d\)](#).

The filing of a notice of appeal under [37 CFR 41.31](#) also closes prosecution of the application. Therefore, an information disclosure statement filed on the same day as or after the mailing date of a notice of appeal must comply with the provisions of [37 CFR 1.97\(d\)](#).

#### A. Information is Used in a New Ground of Rejection

##### 1. Final Rejection is Not Appropriate

If information submitted during the period set forth in [37 CFR 1.97\(c\)](#) with a statement under [37 CFR 1.97\(e\)](#) is used in a new ground of rejection on unamended claims, the next Office action will not be made final since in this situation it is clear that applicant has submitted the information to the Office promptly after it has become known and the information is being submitted prior to a final determination on patentability by the Office.

##### 2. Final Rejection Is Appropriate

The information submitted with a statement under [37 CFR 1.97\(e\)](#) can be used in a new ground of rejection and the next Office action can be made final, if the new ground of rejection was necessitated by amendment of the application by applicant. Where the information is submitted during this period with a fee as set forth in [37 CFR 1.17\(p\)](#), the examiner may use the information submitted, and make the next Office action final whether or not the claims have been amended, provided that no other new ground of rejection which was not necessitated by amendment to the claims is introduced by the examiner. See [MPEP § 706.07\(a\)](#).

### III. INFORMATION DISCLOSURE STATEMENT FILED AFTER II. ABOVE BUT PRIOR TO PAYMENT OF ISSUE FEE (37 CFR 1.97(d))

An information disclosure statement will be considered by the examiner if filed on or after the mailing date of any of the following: a final action under [37 CFR 1.113](#); a notice of allowance under [37 CFR 1.311](#); or an action that closes prosecution in the application, e.g., an *Ex parte Quayle* action, but before or simultaneous with payment of the issue fee, provided the statement is accompanied by:

- (A) a statement as specified in [37 CFR 1.97\(e\)](#) (see the discussion in subsection V; and
- (B) the fee set forth in [37 CFR 1.17\(p\)](#).

These requirements are appropriate in view of the late stage of prosecution when the information is being submitted, i.e., after the examiner has reached a final determination on the patentability of the claims presented for examination. Payment of the fee ([37 CFR 1.17\(p\)](#)) and submission of the appropriate statement ([37 CFR 1.97\(e\)](#)) are the essential elements for having information considered at this advanced stage of prosecution, assuming the content requirements of [37 CFR 1.98](#) are satisfied.

An information disclosure statement filed during this time period will be handled by the examiner as a “Printer Rush”. See [MPEP § 1309.02](#).

Form paragraph 6.52 may be used to inform the applicant that the information disclosure statement is being considered.

#### ¶ 6.52 Information Disclosure Statement Filed After Prosecution Has Been Closed

The information disclosure statement (IDS) submitted on [1] was filed after the mailing date of the [2] on [3]. The submission is in compliance with the provisions of [37 CFR 1.97](#). Accordingly, the information disclosure statement is being considered by the examiner.

##### Examiner Note:

1. In bracket 1, insert the date the IDS was filed.
2. In bracket 2, insert --final Office action--, --Notice of Allowance--, or an -- *Ex parte Quayle* action-- as appropriate.

The requirements of [37 CFR 1.97](#) provide for consideration by the Office of information which is submitted within a reasonable time, i.e., within three

months after an individual designated in [37 CFR 1.56\(c\)](#) becomes aware of the information or within three months of the information being cited in a communication from a foreign patent office in a counterpart foreign application. This undertaking by the Office to consider information would be available throughout the pendency of the application until the point where the patent issue fee was paid.

If an applicant chose not to comply, or could not comply, with the requirements of [37 CFR 1.97\(d\)](#), the applicant may file a RCE under [37 CFR 1.114](#), or a continuing application under [37 CFR 1.53\(b\)](#) (or [37 CFR 1.53\(d\)](#) if the application is a design application) to have the information considered by the examiner. If the applicant files a continuing application under [37 CFR 1.53\(b\)](#), the parent application could be permitted to become abandoned by not paying the issue fee required in the Notice of Allowance. If the prior application is a design application, the filing of a continued prosecution application under [37 CFR 1.53\(d\)](#) automatically abandons the prior application. See the discussion in [MPEP § 609.02](#).

#### **IV. INFORMATION DISCLOSURE STATEMENT FILED AFTER PAYMENT OF ISSUE FEE**

After the issue fee has been paid on an application, it is impractical for the Office to attempt to consider newly submitted information. Information disclosure statements filed after payment of the issue fee in an application will not be considered but will merely be placed in the application file. See [MPEP § 609.05\(b\)](#). The application may be withdrawn from issue at this point, pursuant to [37 CFR 1.313\(c\)\(2\)](#) or [1.313\(c\)\(3\)](#) so that the information can be considered in the application upon the filing of a RCE under [37 CFR 1.114](#) or in a continuing application filed under [37 CFR 1.53\(b\)](#) (or [37 CFR 1.53\(d\)](#) if the application is a design application). In this situation, a RCE, or a CPA (if the prior application is a design application), or a continuing application filed under [37 CFR 1.53\(b\)](#) could be filed even though the issue fee had already been paid. See [MPEP § 1308](#). Applicants are encouraged to file the petition under [37 CFR 1.313\(c\)\(2\)](#) with a RCE, or the petition under [37 CFR 1.313\(c\)\(3\)](#) with a CPA or continuing application under [37 CFR 1.53\(b\)](#), by the USPTO patent electronic filing system (see

[MPEP § 502.05](#)) or facsimile transmission to the Office of Petitions (see [MPEP § 502.01](#), subsection I.B. and [§ 1730](#) for the facsimile number). Alternatively, petitions to withdraw from issue may be hand-carried to the Office of Petitions (see [MPEP § 502](#)). The Office cannot ensure that any petition under [37 CFR 1.313\(c\)](#) will be acted upon prior to the date of patent grant. Applicants considering filing a petition under [37 CFR 1.313\(c\)](#) are encouraged to call the Office of Petitions to determine whether sufficient time remains before the patent issue date to consider and grant a petition under [37 CFR 1.313\(c\)](#). If a petition under [37 CFR 1.313\(c\)\(3\)](#) is being filed by facsimile transmission, the petition need not be accompanied by the information disclosure statement if the size of the statement makes its submission by facsimile impracticable, but the petition should indicate that an IDS will be filed in the continuing application if it does not accompany the petition under [37 CFR 1.313\(c\)\(3\)](#). The IDS should be filed before the mailing of a first Office action on the merits. If a design CPA is being filed and the IDS cannot be filed within this time period, applicants may request a three-month suspension of action under [37 CFR 1.103\(b\)](#) at the time of filing of the design CPA. See the discussion above in paragraph I.B. If a petition under [37 CFR 1.313\(c\)\(2\)](#) is being filed, the RCE must be accompanied by a proper submission in order for the RCE to be in compliance with [37 CFR 1.114](#). Therefore, the IDS must accompany the RCE and the petition under [37 CFR 1.313\(c\)\(2\)](#) if the IDS is the submission for the RCE.

In May of 2012 the Office launched the Quick Path Information Disclosure Statement (QPIDS) Pilot Program. This pilot program allows, under specific circumstances, for the submission of an IDS after payment of the issue fee but prior to patent grant. Information on the QPIDS Pilot Program can be found on the USPTO website [www.uspto.gov/patent/initiatives/quick-path-information-disclosure-statement-qpids](http://www.uspto.gov/patent/initiatives/quick-path-information-disclosure-statement-qpids).

Alternatively, for example, a petition pursuant to [37 CFR 1.313\(c\)\(1\)](#) could be filed if applicant states that one or more claims are unpatentable. This statement that one or more claims are unpatentable over the information must be unequivocal. A statement that a serious question as to patentability

of a claim has been raised, for example, would not be acceptable to withdraw an application from issue under [37 CFR 1.313\(c\)\(1\)](#). Form paragraph 13.09 may be used.

#### ¶ 13.09 Information Disclosure Statement, Issue Fee Paid

Applicant's information disclosure statement of [1] was filed after the issue fee was paid. Information disclosure statements filed after payment of the issue fee will not be considered, but will be placed in the file. However, the application may be withdrawn from issue in order to file a request for continued examination (RCE) under [37 CFR 1.114](#) upon the grant of a petition under [37 CFR 1.313\(c\)\(2\)](#), or a continuing application under [37 CFR 1.53\(b\)](#) (or a continued prosecution application (CPA) under [37 CFR 1.53\(d\)](#) if the CPA is for a design patent and the prior application of the CPA is a design application filed under 35 U.S.C. chapter 16) upon the grant of a petition filed under the provisions of [37 CFR 1.313\(c\)\(3\)](#). Alternatively, the other provisions of [37 CFR 1.313](#) may apply, e.g., a petition to withdraw the application from issue under the provisions of [37 CFR 1.313\(c\)\(1\)](#) may be filed together with an unequivocal statement by the applicant that one or more claims are unpatentable over the information contained in the statement. The information disclosure statement would then be considered upon withdrawal of the application from issue under [37 CFR 1.313\(c\)\(1\)](#).

#### Examiner Note:

1. For information disclosure statements submitted after the issue fee has been paid, use this form paragraph with form PTOL-90 or PTO-90C.
2. In bracket 1, insert the filing date of the IDS.

If an application has been withdrawn from issue under one of the provisions of [37 CFR 1.313\(c\)\(1\)-\(3\)](#), it will be treated as though no notice of allowance had been mailed and the issue fee had not yet been paid with regard to the time for filing information disclosure statements. Petitions under [37 CFR 1.313\(c\)](#) should be directed to the Office of Petitions in the Office of the Deputy Commissioner for Patents who oversees the Office of Petitions. See [MPEP § 1308](#).

#### V. STATEMENT UNDER 37 CFR 1.97(e)

A statement under [37 CFR 1.97\(e\)](#) must state either

- (1) that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- (2) that no item of information contained in the information disclosure statement was cited in a

communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in [37 CFR 1.56\(c\)](#) more than three months prior to the filing of the statement.

A statement under [37 CFR 1.97\(e\)](#) can contain either of two statements. One statement is that each item of information in an information disclosure statement was first cited in any communication, such as a search report, from a patent office outside the U.S. in a counterpart foreign application not more than three months prior to the filing date of the statement. Applicant would not be able to make a statement under [37 CFR 1.97\(e\)](#) where an item of information was first cited by a foreign patent office, for example, a year before the filing of the IDS, in a communication from that foreign patent office, and the same item of information is once again cited by another foreign patent office within three months prior to the filing of the IDS in the Office. Similarly, applicant would not be able to make a statement under [37 CFR 1.97\(e\)](#) where an item of information was cited in an examination report and the same item of information was previously cited more than three months prior to the filing of the IDS in the Office, in a search report from the same foreign patent office. Under this statement, it does not matter whether any individual with a duty of disclosure actually knew about any of the information cited before receiving the search report. Note that compliance with the statement requirement of [37 CFR 1.97\(e\)](#) does not substitute for compliance with [37 CFR 1.704\(d\)](#) when attempting to avoid reduction of patent term adjustment.

The date on the communication by the foreign patent office begins the three-month period in the same manner as the mailing of an Office action starts a three-month shortened statutory period for reply. If the communication contains two dates, the mailing date of the communication is the one which begins the three-month period. The date which begins the three-month period is not the date the communication was received by a foreign associate or the date it was received by a U.S. registered practitioner. Likewise, the statement will be considered to have been filed on the date the statement was received in the Office,

or on an earlier date of mailing or transmission if accompanied by a properly executed certificate of mailing or facsimile transmission under [37 CFR 1.8](#), or if it is in compliance with the provisions for Priority Mail Express® delivery under [37 CFR 1.10](#). If the last day of the three months period set forth in [37 CFR 1.97\(e\)\(1\)](#) and [\(e\)\(2\)](#) falls on a Saturday, Sunday, or a federal holiday within the District of Columbia, the statement under [37 CFR 1.97\(e\)\(1\)](#) or [\(e\)\(2\)](#) may be timely filed on the next succeeding business day which is not a Saturday, Sunday, or a federal holiday. See [37 CFR 1.7\(a\)](#).

The term counterpart foreign patent application means that a claim for priority has been made in either the U.S. application or a foreign application based on the other, or that the disclosures of the U.S. and foreign patent applications are substantively identical (e.g., an application filed in the European Patent Office claiming the same U.K. priority as claimed in the U.S. application). Note, an international application filed under the Patent Cooperation Treaty, which designates the U.S., is not a counterpart foreign application for purposes of making the statement set forth in [37 CFR 1.97\(e\)](#). Therefore, applicant should, instead, consider the applicability of making a statement under [37 CFR 1.97\(e\)\(2\)](#) for information received in an international application.

Communications from foreign patent offices in foreign applications sometimes include a list of the family of patents corresponding to a particular patent being cited in the communication. The family of patents may include a United States patent or other patent in the English language. Some applicants submit information disclosure statements to the PTO which list and include copies of both the particular patent cited in the foreign patent office communication and the related United States or other English language patent from the family list. Since this is to be encouraged, the United States or other English language patent will be construed as being cited by the foreign patent office for purposes of a statement under [37 CFR 1.97\(e\)\(1\)](#). The examiner should consider the United States or other English language patent if [37 CFR 1.97](#) and [37 CFR 1.98](#) are complied with. Further, [37 CFR 1.97\(e\)\(1\)](#) is construed to include any information in a foreign patent office communication, including the

communication itself, such as an office action or search report.

If an information disclosure statement includes a copy of a dated communication from a foreign patent office which clearly shows that the statement is being submitted within three months of the date on the communication, the copy of the dated communication from the foreign patent office by itself will not be accepted as the required statement under [37 CFR 1.97\(e\)\(1\)](#) since it would not be clear from the dated communication whether the information in the IDS was “first cited” in any communication from a foreign patent office not more than three months prior to the filing of the IDS as required by [37 CFR 1.97\(e\)\(1\)](#).

In the alternative, a statement can be made if no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the statement after making reasonable inquiry, neither was it known to any individual having a duty to disclose more than three months prior to the filing of the statement. If an inventor of the U.S. application is also a named inventor of one of the items of information contained in the IDS, the [37 CFR 1.97\(e\)\(2\)](#) statement cannot be made for that particular item of information, and if made, will not be accepted.

The phrase “after making reasonable inquiry” makes it clear that the individual making the statement has a duty to make reasonable inquiry regarding the facts that are being stated. The statement can be made by a registered practitioner who represents a foreign client and who relies on statements made by the foreign client as to the date the information first became known. A registered practitioner who receives information from a client without being informed whether the information was known for more than three months, however, cannot make the statement under [37 CFR 1.97\(e\)\(2\)](#) without making reasonable inquiry. For example, if an inventor gave a publication to the attorney prosecuting an application with the intent that it be cited to the Office, the attorney should inquire as to when that inventor became aware of the publication and should not submit a statement under [37 CFR 1.97\(e\)\(2\)](#) to



the Office until a satisfactory response is received. The statement can be based on present, good faith knowledge about when information became known without a search of files being made.

A statement under [37 CFR 1.97\(e\)](#) need not be in the form of an oath or a declaration under [37 CFR 1.68](#). A statement under [37 CFR 1.97\(e\)](#) by a registered practitioner or any other individual that the statement was filed within the three-month period of either first citation by a foreign patent office or first discovery of the information will be accepted as dispositive of compliance with this provision in the absence of evidence to the contrary. For example, a statement under [37 CFR 1.97\(e\)](#) could read as follows:

I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.,  
or

I hereby state that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in [37 CFR 1.56\(c\)](#) more than three months prior to the filing of this Information Disclosure Statement.

While use of the exact language of [37 CFR 1.97\(e\)\(1\)](#) and/or [37 CFR 1.97\(e\)\(2\)](#) is strongly encouraged, it is not required so long as the language applicant uses conveys the exact same meaning as the language of [37 CFR 1.97\(e\)\(1\)](#) and/or [37 CFR 1.97\(e\)\(2\)](#). Varying the language of the statements runs the risk that it does not convey the same meaning as the language of [37 CFR 1.97\(e\)\(1\)](#) and/or [37 CFR 1.97\(e\)\(2\)](#). If it is determined that the varying language does not (or may not) convey the same meaning, the information disclosure statement will not be accepted.

An information disclosure statement may include two lists and two statements, similar to the above examples, in situations where some of the information listed was cited in a communication from a foreign patent office not more than three months prior to filing the statement and some was not, but was not known more than three months prior to filing the statement. Alternatively, applicant may submit one list with two statements when applicant expressly designates which statement pertains to which citation(s) in the reference listing. If the information is being submitted in the time frame set forth in [37 CFR 1.97\(d\)](#) and applicant includes two statements with either one or two lists on the same day, only one fee is required.

A copy of the foreign search report need not be submitted with the statement under [37 CFR 1.97\(e\)](#), but an individual may wish to submit an English-language version of the search report to satisfy the requirement for a concise explanation where non-English language information is cited. The time at which information was known to any individual designated in [37 CFR 1.56\(c\)](#) is the time when the information was discovered in association with the application even if awareness of the materiality came later. The Office wishes to encourage prompt evaluation of the relevance of information and to have a date certain for determining if a statement under [37 CFR 1.97\(e\)](#) can properly be made. A statement on information and belief would not be sufficient. Examiners should not remind or otherwise make any comment about an individual's duty of candor and good faith. Questions about the adequacy of any statement received in writing by the Office should be directed to the Office of Patent Legal Administration.

#### **VI. EXTENSIONS OF TIME (37 CFR 1.97(f)) AND BONA FIDE ATTEMPT**

No extensions of time for filing an information disclosure statement are permitted under [37 CFR 1.136\(a\)](#) or [\(b\)](#). If a *bona fide* attempt is made to comply with the content requirements of [37 CFR 1.98](#), but part of the required content is inadvertently omitted, additional time may be given to enable full compliance. Form paragraph 6.51 may be used.



### ¶ 6.51 Time for Completing Information Disclosure Statement

The information disclosure statement filed on [1] does not fully comply with the requirements of [37 CFR 1.98\(b\)](#) because: [2]. Since the submission appears to be *bona fide*, applicant is given **ONE (1) MONTH** from the date of this notice to supply the above-mentioned omissions or corrections in the information disclosure statement. NO EXTENSION OF THIS TIME LIMIT MAY BE GRANTED UNDER EITHER [37 CFR 1.136\(a\)](#) OR [\(b\)](#). Failure to timely comply with this notice will result in the above-mentioned information disclosure statement being placed in the application file with the non-complying information **not** being considered. See [37 CFR 1.97\(i\)](#).

#### Examiner Note:

Use this form paragraph if an IDS complies with the timing requirements of [37 CFR 1.97](#) but part of the content requirements of [37 CFR 1.98\(b\)](#) has been inadvertently omitted.

This practice does not apply where there has been a deliberate omission of some necessary part of an Information Disclosure Statement or where the requirements based on the time of filing the statement, as set forth in [37 CFR 1.97](#), have not been complied with.

## 609.05 Examiner Handling of Information Disclosure Statements [R-08.2012]

Information disclosure statements will be reviewed for compliance with the requirements of [37 CFR 1.97](#) and [37 CFR 1.98](#) as discussed in [MPEP § 609.04\(a\)](#) and [§ 609.04\(b\)](#). Applicant will be notified of compliance and noncompliance with the rules as discussed in [MPEP § 609.05\(a\)](#) and [§ 609.05\(b\)](#).

### 609.05(a) Noncomplying Information Disclosure Statements [R-07.2022]

Pursuant to [37 CFR 1.97\(i\)](#), submitted information, filed before the grant of a patent, which does not comply with [37 CFR 1.97](#) and [37 CFR 1.98](#) will be placed in the file, but will not be considered by the Office. Information submitted after the grant of a patent must comply with [37 CFR 1.501](#).

If an information disclosure statement does not comply with the requirements based on the time of filing of the IDS as discussed in [MPEP § 609.04\(b\)](#), including the requirements for fees and/or statement under [37 CFR 1.97\(e\)](#), the IDS will be placed in the application file, but none of the information will be considered by the examiner. The examiner may use form paragraph 6.49 which is reproduced below to

inform applicant that the information has not been considered. Applicant may then file a new information disclosure statement or correct the deficiency in the previously filed IDS, but the date that the new IDS or correction is filed will be the date of the IDS for purposes of determining compliance with the requirements based on the time of filing of the IDS ([37 CFR 1.97](#)).

The examiner should write “not considered” on an information disclosure statement where none of the information listed complies with the requirements, e.g., the format requirements of [37 CFR 1.98\(a\)\(1\)](#) are not met. If none of the information listed on a PTO/SB/08 form is considered, a diagonal line or "X" should also be drawn across the form and the form made of record in the application file. The examiner will inform applicant that the information has not been considered and the reasons why by using form paragraphs 6.49 through 6.49.10. If the improper citation appears as part of another paper, e.g., an amendment, which may be properly entered and considered, the portion of the paper which is proper for consideration will be considered.

If an item of information in an IDS fails to comply with all the requirements of [37 CFR 1.97](#) and [37 CFR 1.98](#), that item of information in the IDS will not be considered and a line should be drawn through the citation to show that it has not been considered. However, other items of information that do comply with all the requirements of [37 CFR 1.97](#) and [37 CFR 1.98](#) will be considered by the examiner.

If information listed in the specification rather than in a separate paper, or if the other content requirements as discussed in [MPEP § 609.04\(a\)](#) are not complied with, the information need not be considered by the examiner, in which case, the examiner should notify applicant in the next Office action that the information has not been considered.

## FORM PARAGRAPHS

### ¶ 6.49 Information Disclosure Statement Not Considered

The information disclosure statement filed [1] fails to comply with the provisions of [37 CFR 1.97](#), [1.98](#) and [MPEP § 609](#) because [2]. It has been placed in the application file, but the information referred to therein has not been considered as to the merits. Applicant is advised that the date of any resubmission of any item of information contained in this information

disclosure statement or the submission of any missing element(s) will be the date of submission for purposes of determining compliance with the requirements based on the time of filing the statement, including all requirements for statements under [37 CFR 1.97\(e\)](#). See [MPEP § 609.05\(a\)](#).

#### **Examiner Note:**

See [MPEP § 609.05\(a\)](#) for situations where the use of this form paragraph would be appropriate.

#### **¶ 6.49.01 Information Disclosure Statement Not Considered, After First Action, But Before the Prosecution of the Application Closes, No Statement**

The information disclosure statement filed [1] fails to comply with [37 CFR 1.97\(c\)](#) because it lacks a statement as specified in [37 CFR 1.97\(e\)](#). It has been placed in the application file, but the information referred to therein has not been considered.

#### **¶ 6.49.02 Information Disclosure Statement Not Considered, After First Action, But Before the Prosecution of the Application Closes, No Fee**

The information disclosure statement filed [1] fails to comply with [37 CFR 1.97\(c\)](#) because it lacks the fee set forth in [37 CFR 1.17\(p\)](#). It has been placed in the application file, but the information referred to therein has not been considered.

#### **¶ 6.49.03 Information Disclosure Statement Not Considered, After the Prosecution of the Application Closes, Issue Fee Not Paid, No Statement**

The information disclosure statement filed [1] fails to comply with [37 CFR 1.97\(d\)](#) because it lacks a statement as specified in [37 CFR 1.97\(e\)](#). It has been placed in the application file, but the information referred to therein has not been considered.

#### **¶ 6.49.05 Information Disclosure Statement Not Considered, After the Prosecution of the Application Closes, Issue Fee Not Paid, No Fee**

The information disclosure statement filed [1] fails to comply with [37 CFR 1.97\(d\)](#) because it lacks the fee set forth in [37 CFR 1.17\(p\)](#). It has been placed in the application file, but the information referred to therein has not been considered.

#### **¶ 6.49.06 Information Disclosure Statement Not Considered, References Listed in Specification**

The listing of references in the specification is not a proper information disclosure statement. [37 CFR 1.98\(b\)](#) requires a list of all patents, publications, applications, or other information submitted for consideration by the Office, and [MPEP § 609.04\(a\)](#), subsection I, states, “the list may not be incorporated into the specification but must be submitted in a separate paper.” Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

#### **¶ 6.49.07 Information Disclosure Statement Not Considered, No Copy of References**

The information disclosure statement filed [1] fails to comply with [37 CFR 1.98\(a\)\(2\)](#), which requires a legible copy of each cited foreign patent document; each non-patent literature

publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered.

#### **Examiner Note:**

Do not use this form paragraph when the missing reference(s) are U.S. patents, U.S. patent application publications, or U.S. pending applications (limited to the specification, including claims, and drawings) stored in IFW.

#### **¶ 6.49.08 Information Disclosure Statement Not Considered, Non-Compliant List of References**

The information disclosure statement filed [1] fails to comply with [37 CFR 1.98\(a\)\(1\)](#), which requires the following: (1) a list of all patents, publications, applications, or other information submitted for consideration by the Office; (2) U.S. patents and U.S. patent application publications listed in a section separately from citations of other documents; (3) the application number of the application in which the information disclosure statement is being submitted on each page of the list; (4) a column that provides a blank space next to each document to be considered, for the examiner’s initials; and (5) a heading that clearly indicates that the list is an information disclosure statement. The information disclosure statement has been placed in the application file, but the information referred to therein has not been considered.

#### **Examiner Note:**

If an IDS listing includes a copy of an initialed IDS listing from another application, the IDS listing would not comply with the requirements under [37 CFR 1.98\(a\)\(1\)](#). This form paragraph is applicable for such an IDS submission.

#### **¶ 6.49.09 Information Disclosure Statement Not Considered, No Explanation of Relevance of Non-English Language Information**

The information disclosure statement filed [1] fails to comply with [37 CFR 1.98\(a\)\(3\)\(i\)](#) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in [37 CFR 1.56\(c\)](#) most knowledgeable about the content of the information, of each reference listed that is not in the English language. It has been placed in the application file, but the information referred to therein has not been considered.

#### **¶ 6.49.10 Information Disclosure Statement Not Considered, Non-acceptable Electronic Medium**

The information disclosure statement filed [1] was submitted on an electronic medium that was not acceptable. It has been placed in the application file, but the information referred to therein has not been considered. Note that U.S. patents, U.S. application publications, foreign patent documents and non-patent literature cited in an information disclosure statement may be electronically submitted in compliance with the Office Electronic Filing System (EFS) requirements.

**Examiner Note:**

This form paragraph may be used when the IDS that includes patents and non-patent literature documents is submitted on read-only optical discs or any other electronic medium, except via EFS. Only “Large Tables,” “Sequence Listings,” a computer readable form of a “Sequence Listing” and a “Computer Program Listing Appendix” may be submitted on one or more read-only optical discs. See [37 CFR 1.52\(e\)](#).

**609.05(b) Complying Information Disclosure Statements [R-07.2022]**

The information contained in information disclosure statements which comply with both the content requirements of [37 CFR 1.98](#) and the requirements, based on the time of filing the statement, of [37 CFR 1.97](#) will be considered by the examiner. Consideration by the examiner of the information submitted in an IDS means that the examiner will consider the documents in the same manner as other documents in Office search files are considered by the examiner while conducting a search of the prior art in a proper field of search. The initials of the examiner placed adjacent to the citations on the PTO/SB/08 or its equivalent mean that the information has been considered by the examiner to the extent noted above.

In addition, the following alternative electronic signature method may be used by examiners in information disclosure statements to indicate whether the information has been considered. Examiners will no longer initial each reference citation considered, but will continue to strikethrough each citation not considered. Each page of reference citations will be stamped by the examiner with the phrase “All references considered except where lined through” along with the examiner’s electronic initials, and the final page of reference citations will include the examiner’s electronic signature.

Examiners must consider all citations submitted in conformance with the rules, and their initials when placed adjacent to the considered citations on the list or in the boxes provided on a form PTO/SB/08 (or the examiner may use the alternative electronic signature method noted above) provides a clear record of which citations have been considered by the Office. The examiner must also fill in the examiner’s name and the date the information was considered in blocks at the bottom of the PTO/SB/08

form. If any of the citations are considered, a copy of the submitted list, form PTO/SB/08, as reviewed by the examiner, will be returned to the applicant with the next communication. Those citations not considered by the examiner will have a line drawn through the citation. The original copy of the list, form PTO/SB/08, will be entered into the application file. The copy returned to applicant will serve both as acknowledgement of receipt of the information disclosure statement and as an indication as to which references were considered by the examiner. Forms PTO-326 and PTOL-37 include a box to indicate the attachment of form PTO/SB/08.

Information which complies with requirements as discussed in this section but which is in a non-English language will be considered in view of the concise explanation submitted (see [MPEP § 609.04\(a\)](#), subsection III.) and insofar as it is understood on its face, e.g., drawings, chemical formulas, in the same manner that non-English language information in Office search files is considered by examiners in conducting searches. The examiner need not have the information translated unless it appears to be necessary to do so. The examiner will indicate that the non-English language information has been considered in the same manner as consideration is indicated for information submitted in English. The examiner should not require that a translation be filed by applicant. The examiner should not make any comment such as that the non-English language information has only been considered to the extent understood, since this fact is inherent. See *Semiconductor Energy Laboratory Co. v. Samsung Electronics Co.*, 204 F.3d 1368, 1377-78, 54 USPQ2d 1001, 1008 (Fed. Cir. 2000) (“[A]s MPEP Section 609C(2) reveals, the examiner’s understanding of a foreign reference is generally limited to that which he or she can glean from the applicant’s concise statement...Consequently, while the examiner’s initials require that we presume that he or she considered the [foreign] reference, this presumption extends only to the examiner’s consideration of the brief translated portion and the concise statement.”).

If an item of information in an IDS fails to comply with requirements of [37 CFR 1.97](#) and [37 CFR 1.98](#), a line should be drawn through the citation to show

that it has not been considered. The other items of information listed that do comply with the requirements of [37 CFR 1.97](#) and [37 CFR 1.98](#) will be considered by the examiner and will be appropriately initialed.

### **609.05(c) Documents Submitted as Part of Applicant's Reply to Office Action [R-07.2022]**

Occasionally, documents are submitted and relied on by an applicant when replying to an Office action. These documents may be relied on by an applicant, for example, to show that an element recited in the claim is operative or that a term used in the claim has a recognized meaning in the art. Documents may be in any form but are typically in the form of an affidavit, declaration, patent, or printed publication.

To the extent that a document is submitted as evidence directed to an issue of patentability raised in an Office action, and the evidence is timely presented, applicant need not satisfy the requirements of [37 CFR 1.97](#) and [37 CFR 1.98](#) in order to have the examiner consider the information contained in the document relied on by applicant. In other words, compliance with the information disclosure rules is not a threshold requirement to have information considered when submitted by applicant to support an argument being made in a reply to an Office action. However, consideration by the examiner of the document submitted as evidence directed to an issue of patentability raised in the Office action is limited to the portion of the document relied upon as rebuttal evidence; the entirety of the document may not necessarily be considered by the examiner.

At the same time, the document supplied and relied on by applicant as evidence need not be processed as an item of information that was cited in an information disclosure statement. The record should reflect whether the evidence was considered, but listing on a form (e.g., PTO-892 or PTO/SB/08) and appropriate marking of the form by the examiner is not required.

For example, if applicant submits and relies on three patents as evidence in reply to the first Office action and also lists those patents on a PTO/SB/08 along with two journal articles, but does not file a

statement under [37 CFR 1.97\(e\)](#) or the fee set forth in [37 CFR 1.17\(p\)](#), it would be appropriate for the examiner to indicate that the teachings relied on by applicant in the three patents have been considered, but to line through the citation of all five documents on the PTO/SB/08 and to inform applicant that the information disclosure statement did not comply with [37 CFR 1.97\(c\)](#).

### **609.06 Information Printed on Patent [R-07.2022]**

A citation listed on form PTO/SB/08 and considered by the examiner will be printed on the patent. A citation listed in a separate paper, equivalent to but not on form PTO/SB/08, and considered by the examiner will be printed on the patent if the list lends itself to easy capture of the necessary information by the Office printing contractor, i.e., each item of information is listed on a single line, the lines are at least double-spaced from each other, and the information is uniform in format for each listed item. For patents printed after January 1, 2001, citations from information disclosure statements that are printed on the face of the patent will be distinguished from citations cited by the examiner on a form PTO-892. The citations cited by the examiner on a form PTO-892 will be marked with an asterisk. If an item of information is cited more than once in an IDS and on a form PTO-892, the citation of the item will be listed only once on the patent as a citation cited by the examiner.

If the applicant does not provide classification information for a citation, or if the examiner lines through incorrect classification data, the citation will be printed on the face of the patent without the classification information. If a U.S. patent application number is listed on a PTO/SB/08 form or its equivalent and the examiner considers the information and initials the form, the application number will be printed on the patent. Applicants may wish to list U.S. patent application numbers on other than a form PTO/SB/08 format to avoid the application numbers of pending applications being published on the patent. If a citation is not printed on the patent but has been considered by the examiner, the patented file will reflect that fact as noted in [MPEP § 609.05\(b\)](#).



### 609.07 IDSs Electronically Submitted (e-IDS) Using EFS-Web [R-07.2022]

Information disclosure statements may be submitted to the Office via the USPTO patent electronic filing system. Applicants can file an e-IDS using EFS-Web by (A) entering the references' citation information in an electronic data entry form, equivalent to the paper PTO/SB/08 form, and (B) transmitting the electronic data entry form to the Office. An e-IDS filed via EFS-Web may include citations of U.S. patents, U.S. patent application publications, foreign patent documents, and non-patent literature (NPLs). Copies of U.S. patents and U.S. patent application publications cited in the IDS are not required to be submitted by the applicants with the e-IDS. If any references to foreign patent documents or NPLs or unpublished U.S. patent applications (that are not stored in the Office's Image File Wrapper (IFW) system) are to be cited, applicants must submit copies of these documents in PDF using EFS-Web.

The electronic IDS form may be included with a new EFS-Web electronic application filing, or it may be submitted for previously filed patent applications. An e-IDS contains an electronic list of U.S. patent numbers, U.S. patent application publication numbers, foreign patent documents and non-patent literature (NPLs). An individual e-IDS may contain a listing of (1) a combined total of 50 U.S. patents and U.S. patent application publications, (2) 50 foreign patent documents, and (3) 50 NPLs. Applicants are permitted to file more than one e-IDS if these numbers are exceeded.

If more than one e-IDS is necessary to file a complete IDS for which a fee is required under [37 CFR 1.17\(p\)](#), only a single fee under [37 CFR 1.17\(p\)](#) will be required under the following conditions:

(A) the fee required by [37 CFR 1.17\(p\)](#) is included with the first e-IDS submission (since it will normally be processed first);

(B) all subsequent submissions making up the IDS should explicitly state that the fee was included in the earlier submission and request that the one fee be accepted for the second and any subsequent submission; and

(C) all subsequent submissions (electronic or paper) must be received by the Office on the same

date as the first e-IDS submission with which the fee was included.

A subsequent non-electronic submission is considered received by the Office on the same date as the first e-IDS submission with which the fee was included for purposes of the fee due under [37 CFR 1.17\(p\)](#) if it is deposited in Priority Mail Express® under [37 CFR 1.10](#), deposited in the first class U.S. mail with a certificate of mailing in accordance with [37 CFR 1.8](#), or transmitted by facsimile with a certificate of transmission in accordance with [37 CFR 1.8](#), on the same date as the first e-IDS submission with which the fee was included. If a subsequent e-IDS submission is received by the Office on a date later than the date the fee was paid, the later submission will require an additional fee.

A copy of the e-IDS form will be scanned to become part of the Image File Wrapper (IFW). In all applications, the e-IDS will be added to the application file contents listing, and to the Patent Data Portal database record for the application.

If the e-IDS complies with the requirements of [37 CFR 1.97](#), examiners must consider the e-IDS and complete the e-IDS form by initialing, signing, and dating the e-IDS form entries. See [MPEP § 609.05\(b\)](#). Examiners may notice numbering gaps in the "Citation No." column on the printed e-IDS form due to an applicant data entry error. This data entry error will not affect the e-IDS and is not a sufficient reason not to consider the e-IDS. A copy of the initialed e-IDS form must be sent to the applicant. The completed copy of the e-IDS form sent to an applicant should be made of record in the official file when the copy is sent to the applicant.

An electronic list of all U.S. patents and U.S. patent application publications on an e-IDS form is available and accessible from the examiner's workstation by clicking on the e-IDS icon, on the workstation desktop. Consideration of the e-IDS may not be deferred and an examiner should not require an applicant to submit paper copies of e-IDS references. It is most important that the U.S. patent and U.S. patent application publication numbers listed on the e-IDS be accurate and devoid of transcription error since no copies of the documents listed on the e-IDS are provided in the file wrapper for the examiner to review. Instead the examiner

will electronically retrieve the U.S. patents and U.S. patent application publications identified by the cited document numbers. The only mechanism for having the correct document reviewed and considered when an erroneous U.S. patent or U.S. patent application publication is cited in an e-IDS will be by citing the correct citation number in a subsequent IDS that conforms to the requirements of [37 CFR 1.97](#) and [1.98](#).

Examiners can copy and paste U.S. patent and U.S. patent application publication numbers from the e-IDS to EAST and/or WEST for searching. Examiners should copy and paste U.S. patent and U.S. patent application publication numbers from the e-IDS to EAST and/or WEST to review the references that are listed in the e-IDS.

Applicants and registered practitioners are permitted to sign portions of an EFS-Web submission, including an IDS, with an electronic signature. See [37 CFR 1.4\(d\)\(3\)](#).

If the e-IDS transmittal letter and list of references is missing from an application file, an examiner may request that the technical support staff obtain an additional printed copy of the letter and reference list from the Office of Patent Application Processing (OPAP).

### **609.08 Electronic Processing of Information Disclosure Statement [R-07.2022]**

The USPTO electronically processes the list of citations (e.g., form PTO/SB/08) submitted as part of an information disclosure statement (IDS) submitted in applications stored by the Office in image form. Examiners are provided with a tool to electronically annotate citations and electronically sign the IDS when reviewing the cited references. See [MPEP § 609.04\(b\)](#) for determining whether a cited reference has been considered by the examiner. The electronically processed IDS will be stored in the Office's official record as an entry in the application's image file wrapper (IFW) and a copy will be provided to applicant as part of an Office action.



## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. The United States Patent and Trademark Office (USPTO) collects the information in this record under authority of 35 U.S.C. 2. The USPTO's system of records is used to manage all applicant and owner information including name, citizenship, residence, post office address, and other information with respect to inventors and their legal representatives pertaining to the applicant's/owner's activities in connection with the invention for which a patent is sought or has been granted. The applicable Privacy Act System of Records Notice for the information collected in this form is COMMERCE/PAT-TM-7 Patent Application Files, available in the Federal Register at 78 FR 19243 (March 29, 2013). <https://www.govinfo.gov/content/pkg/FR-2013-03-29/pdf/2013-07341.pdf>

Routine uses of the information in this record may include disclosure to: 1) law enforcement, in the event that the system of records indicates a violation or potential violation of law; 2) a Federal, state, local, or international agency, in response to its request; 3) a contractor of the USPTO having need for the information in order to perform a contract; 4) the Department of Justice for determination of whether the Freedom of Information Act (FOIA) requires disclosure of the record; 5) a Member of Congress submitting a request involving an individual to whom the record pertains, when the individual has requested the Member's assistance with respect to the subject matter of the record; 6) a court, magistrate, or administrative tribunal, in the course of presenting evidence, including disclosures to opposing counsel in the course of settlement negotiations; 7) the Administrator, General Services Administration (GSA), or their designee, during an inspection of records conducted by GSA under authority of 44 U.S.C. 2904 and 2906, in accordance with the GSA regulations and any other relevant (i.e., GSA or Commerce) directive, where such disclosure shall not be used to make determinations about individuals; 8) another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)); 9) the Office of Personnel Management (OPM) for personnel research purposes; and 9) the Office of Management and Budget (OMB) for legislative coordination and clearance.

If you do not furnish the information requested on this form, the USPTO may not be able to process and/or examine your submission, which may result in termination of proceedings, abandonment of the application, and/or expiration of the patent.

## Additional Uses

Additional USPTO uses of the information in this record may include disclosure to: 1) the International Bureau of the World Intellectual Property Organization, if the record is related to an international application filed under the Patent Cooperation Treaty; 2) the public i) after publication of the application pursuant to 35 U.S.C. 122(b), ii) after issuance of a patent pursuant to 35 U.S.C. 151, iii) if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections, or an issued patent, or iv) without publication of the application or patent under the specific circumstances provided for by 37 CFR 1.14(a)(1)(v)-(vii); and/or 3) the National Archives and Records Administration, for inspection of records.





## Privacy Act Statement

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. The United States Patent and Trademark Office (USPTO) collects the information in this record under authority of 35 U.S.C. 2. The USPTO's system of records is used to manage all applicant and owner information including name, citizenship, residence, post office address, and other information with respect to inventors and their legal representatives pertaining to the applicant's/owner's activities in connection with the invention for which a patent is sought or has been granted. The applicable Privacy Act System of Records Notice for the information collected in this form is COMMERCE/PAT-TM-7 Patent Application Files, available in the Federal Register at 78 FR 19243 (March 29, 2013). <https://www.govinfo.gov/content/pkg/FR-2013-03-29/pdf/2013-07341.pdf>

Routine uses of the information in this record may include disclosure to: 1) law enforcement, in the event that the system of records indicates a violation or potential violation of law; 2) a Federal, state, local, or international agency, in response to its request; 3) a contractor of the USPTO having need for the information in order to perform a contract; 4) the Department of Justice for determination of whether the Freedom of Information Act (FOIA) requires disclosure of the record; 5) a Member of Congress submitting a request involving an individual to whom the record pertains, when the individual has requested the Member's assistance with respect to the subject matter of the record; 6) a court, magistrate, or administrative tribunal, in the course of presenting evidence, including disclosures to opposing counsel in the course of settlement negotiations; 7) the Administrator, General Services Administration (GSA), or their designee, during an inspection of records conducted by GSA under authority of 44 U.S.C. 2904 and 2906, in accordance with the GSA regulations and any other relevant (i.e., GSA or Commerce) directive, where such disclosure shall not be used to make determinations about individuals; 8) another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)); 9) the Office of Personnel Management (OPM) for personnel research purposes; and 9) the Office of Management and Budget (OMB) for legislative coordination and clearance.

If you do not furnish the information requested on this form, the USPTO may not be able to process and/or examine your submission, which may result in termination of proceedings, abandonment of the application, and/or expiration of the patent.

## Additional Uses

Additional USPTO uses of the information in this record may include disclosure to: 1) the International Bureau of the World Intellectual Property Organization, if the record is related to an international application filed under the Patent Cooperation Treaty; 2) the public i) after publication of the application pursuant to 35 U.S.C. 122(b), ii) after issuance of a patent pursuant to 35 U.S.C. 151, iii) if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections, or an issued patent, or iv) without publication of the application or patent under the specific circumstances provided for by 37 CFR 1.14(a)(1)(v)-(vii); and/or 3) the National Archives and Records Administration, for inspection of records.